MADE IN TIIE U . S . A.

/PATENT PENDING :

T II E C R A N E R E P 0 R T

For Limited Circulation Only Within Rife Laboratory

Te xt : pages 1-14
Appendix: pages 15-46

The original version was incomplete, missing many pages. We have now inserted
nearly all the missing pages (only Appendix T, page 40 is missing) and extended it
by including the full patent in Appendix Z. Released: www.rife.de on May 22, 2017
 Introduction -- Rife and Crane

Before examining the issues and papers pertaining to patenting

of the Rife-Crane cancer cure technology , it is best if the history
of the cure ' s development be fully und erstood . This hi story is
described in a report titled THE CANCER CURE THAT WORKE D: 50 YEARS
OF SUPPRESSION. It provides the n ecessary overview . For easy
refere n ce , i t is commonly termed in correspondence THE RIFE REPORT
or RR. The report you are holding now, titled THE CRANE REPORT or
CR, may be viewed as an essential suppl e ment to RR. However, while
th~ RIFE REPORT is for gene ral circulation and is copyrighted, THE
CRANE REPORT is for limited circulation within Rife Laboratory. If
yo~ receive a copy , i t is with the understanding that i t will not
be copied or shown to anyone else without authority from the managers
of Rife Laboratory. Changes are expected to be made in this report
as i t evolves .

THE RI FE REPORT describes (1) h o w Roy Rife invented a super

microscope which enabled scientists to see viruses in their live
state and '' sta in'' the viruses with color instead of chemicals; (2)
how Roy Rife invented Frequency In struments (FI) which, using
electronic frequencies set on the unique rate of each virus, destroyed
them in slides , in animals , and in humans; (3) how medical, pharma-
ceutical, cancer and political authorities combined to suppress the
discovery and its various techniques .

What is not covered in THE RIFE REPORT is that in 1950 Rife

became partners with John Crane and the microscope and Frequency
Instruments were not only improved and further developed through a
cooperative effort, but re -inve nted according to a new d es ign of
John Crane ' s . It is Rife ' s and Crane ' s inventions which a patent
approval will be sought.

Rife died in 1972. Crane is alive . Crane applied for patents

in 1969 . Rife had sold all his material s and early instruments to
Crane by then. He also prepared a le gal document specifying that
any patent granted in his name should be assigned to Crane and Crane's
•
assignees.

Bec ause Crane ' s patent application (1) combined several inventions;
(2) .did not adhere . to Patent Office standards and proc e dures; (3) were
negligently haridl~d -- as the Patent Office ~dmitted in a letter to
Crane ' s Congressional representative -- the years 1969 -1973 witn essed
a Patent Office blunder of monumental proportions. The patent
applications of 1969 and 1971 clearly state that the cure for cancer
and other diseases was availabl e because of this technology . Yet the
application was . treated in a bureaucratically narrow and apparently
offhand fashion -- whil e hundieds 6f thousands of Ameri cahs , incl~ding
children, died annually and continue to die (480,000 a y e ar is the
curre nt rate) .

It is possibl e tha t patenting of the ca n cer cure ca nno t b e

obtained and that control and protection of the technol <)q y will have
t o b e soug ht through t r ade s.e cret provisions in lea s in9 co ntracts or
even the es tablishme nt of unique hea li n g ce nters. Ho wever , i t is
also poss ible that some critical el ements of the tec hnology still
ca n be pro tected as a res ult of approval by th e Pa te n t Of fi ce or
because of e ither judicia l or legisl~tiv e acticin .
l
 2

For this reason, i t is essential that the patent attorney not

only have the required expertise, but also an appreciation of the
social importance of the technology and perhaps a " fire in the belly ."
A crime has taken place here and i t is monstrous. The numbers of
Americans who have died because of the cancer cure's suppression
exceed those murdered by Hitler or Stalin.

It is also worth keeping in mind that, given the circumstances,

a special Congressional Act might provide legal protection not
possible through orthodox channels. With AIDS now a growing health
threat and the clear likelihood that the Rife-Crane technology can
cure and prevent the spread
·- of AIDS, if not eradicate it, such
special political legislation ought not be dismissed as impossible .
A public furor concerning this matter is a distinct possibility --
out of which could emerge the foundation for an e ntirely different
health treatme nt and disease prevention system.

Therefore, from the outset , the attitude of the patent attorney,

and indeed all others associated with this endeavor, shou ld be
''vi sionary '' as well as realistic .

Patenting Summary

The question of patenting the cure for cancer is crucial to any

business plan or indeed general direction for Rife Laboratory. Not
only isit a major element in interesting investers, but it also
involves the essential choices regarding how resources will be used.
This summary will outline some of the problems, some of the options,
and perhaps serve as an initial working paper for developing a broad
range of policies.

While a patent attorney obviously knows the law, the loopholes,

various strategies and more than the author could learn in a year's
research, he does have an overview which any patent attorney will
lack upon initial examination of this matter. Therefo re, it is
certain that this report can be valuable. Nevertheless , in presenting
facts critical t:o the ultimate patenti ng decisions, the author i .s
aware that many ideas or perhaps notion s included h ere will be
worthless . Hopefully, a few may be worth developing.

A patent provides a monopoly for 17 years from the time it is

issued. Thus, as in the extreme case where Gene ral Motors fought
the Patent Office. through 3. court trials for 26 years , upon winn ing ,
the patent provided General Motors with a protection for their ·
invention that lasted for the next 17 years. It also protected them
against any infringement which took place during the previous 26 years
of litigation . · ·
 3

The patent monopoly is granted for the limited time of 17 years

with the understanding that ''full disclosure'' be made in public
records. Thus, when the patent runs out, the invention is in the
public domain and anyone can use it. Lincoln, in a famous saying,
proclaimed, "The patent system added the fuel of interest to the
fire of genius.'' The patent system rewards the inventor(s) financially.
That is integral to the system. But the price of that monopoly is
that the inventor bring his system to the public and after a period
of time, it belongs to everyone.

· The Patent Office's role is to ensure that the invention is

ori~inal and ''useful.'' Usefulness is a key point as will be seen.
Patent examiners have been known to cite ancient writings to show an
idea is not original. This also brings forth a critical point --
publishing one's ideas before attempting to patent them is grounds
for denying a pate~t. The ''publication" can consist of as little as
one typed manuscript b~ing placed in one library. The author will
return to this point later because it obviously is central to the
cancer cure inasmuch as there are published writings by Rife and
Crane or about Rife and Crane prior to Crane's initial 1969 patent
submission.

Another reason for denying a patent is ''public sale'' of the

invention prior to the patenting. More on this later.

It should be kept in mind that it is in the government's interest

to encourage useful inventions and thus grant a limited monopoly for
a time in order that the invention ultimately be put in the public
domain. However, an inventor who goes the ''trade secrets'' route keeps
the commercial value for as long as he can protect the secrets and
control the interest of his market. The formula for coca-cola has
never been patented. It is a closely guarded secret. Whether such
a direction would be possible with the Frequency Instrument or even
appropriate seems highly unlikely to the author of this report,
although the microscope might fit such a program.
-
One important exception to the ''public sale'' criteria is that
a use in public is not a ''public use'' if it is genuinely experimental.
As a necessary step in bringing about a working, us eful model, public
experimentation may not inval.idate a patent claim. In this situation,
r equiri ng doctors' results before an announcement that a cancer cure
existed, the sale of the early models possibly may n ot have invalidated
the later patenting. This is especially relevant because of the AMA,
FDA quashing of those involved and the fact that ~s 1986 ended, no
cure of cancer by this t ec hnology is practiced or publicly known.
Obviously this~ "experimental use" exception could be a critical
point for later litigation -- a·ffecting all aspects of the patent
request (in proceeding with the Patent Office or other channels).

However, the "prior publishing" and "pr ior sale" restrictions

should not be dismissed as easy obstacles. On these two gualif ication
points of patent law and t ra d i t io n, the Patent Offic e , the courts ,
t he government 's ''public interest'' a nd a host of competitive manufac-
tur e rs (including AMA-affiliated interests ) could sue in order to gain
the right to produce Frequency Instruments. The record will provide
them witl1 mount~ins o f argume nt.
 4

It is also impo r tant to keep in mind that having a pate nt means

nothing if you lose a court case . The Patent Office sits on the
sideli n e . The patent h o l der mus t defend himse l f any a n d e very time
h e is c h al l e n ged . With the money at stake here , we can assume that
even a pa t ent will not prevent us from being challenged in the
courts. One argument i n our favor may be that the simplicity o f
the Frequency Instrument makes it in the nation ' s interest to grant
a patent . Otherwise , · cheap Asian copies of the Frequency Instrument
are almost certain . Made in the U.S.A . /Patent Pending was us e d as
t h e ti tl e of t h is rep o r t for qui t e specif i c r easons . We potentially
have a chance to establish an entire n e w industry which could r everse
some of America ' s technological/industrial trade problems. This may
be bur stronge st legal p osi tion, polit ical ~hough it may be .

A footnote to t h is entire question of patenting is that by

openly printing the details of an invention , an inventor preve nts
anyone e l se from paten ti n g that i nvention . Th is is ra ther importan t
because a p ate n t was issued on a F r equency In strument i n November
1986 . While the 36 year old doctor ' s patent i nvolved stimulating
the production of interferon in cells , not the de s truction of cancer
virus , i t is a Frequency Instrument treatment of cancer . He could
theoretically prevent ·u s from manufacturing Freque n c y I nstrume nts
unless we showe d Rife ' s and Crane ' s published ~eports invalidated
his patent. {~e.e. Arr~ \. tU \.>Z. Z ..ktr d.E- ~ l Is)
ope.o':>
This 1986 patent ~ a variety of options. The first is that
we have one year to file with the Pate nt Office a nd contest the
granting of that patent . Reading a patent for a Frequency Instrumen t
also will e n abl e us to see how one is approved . (Comparing the
approved version to the rejected applications of John Crane in the
1969-1973 period.) A third choice is to join for ces with thi s doctor
at a late r stage . He is young , obviously has exper ience and interest
in the field , a nd certainly we have y ears of development bef ore us .
A book titl ed INSIDE THE U. S . PATENT OFFICE states:

'' An interference may also arise after a patent has

been issued if t h e p~tent is not mor e than 1 yea r old ;
and the pa t ente e may lose hi s patent if the inte rfere nce
proce e dings should go again st him . An interferenc e
pr oceedi ng is h eld under the aus pices of the Paten t Office
and the decision regarding priority of i nvention is made
by a Boa rd of Interference.

"On more than one occasion, however , interferences

h ave been r esolved b y t h e parties t hemselves , throu gh
mutua l agreement . ''

Another consideration is that a new application for a pa te nt

takes an average of 2 yea rs to be. concluded . Th.e re is no possibility
of waiti ng for a patent approval -- e v e n if there weren ' t exceptional
obstacles such as e x is t here -- befo re manufactu ring and using the
Fr e quency In stru me nts on despe rat e , dyi n g peopl e ( i nc ludin g c hildren).
Whil e it ma y be poss ibl e to speed up the patent process th r o ugh a
specia l peti tion and reactivation of the ' 6 9 claim, we can ' t d e vote
major attention to the patent proces s at the expense o f makin g actu al
treatmen t avail able . Obviously , any investor who s tresses the
patenting as necessa ry before he can come in should be politely
 5

informed that he wants an unrealistic security -- discussions shou ld

cease immediately.

On the question of refiling , any patent app lication tha t i s

rej e cted can be reinitiate d with a new application. The details of
rejected patent applications are n o t made public. Even more
significant, an application f o r a patent ma y b e abandoned and
subsequently rene wed with the approval of the Patent Office.

· A few more relevant f act s -- (1) a patent ca n be extended by

an' Act of Congress under special circumstances (perhaps a pate nt
such · as this can be granted in a similar way); (2) an applicatio n
can be examined with priority, bypassing those filed ahead of it
(again, under spe cial conditions); (3) a patent can be granted t o
a dead man if an application is filed by the inve ntor's executor
or administrator (pertains to Rife, not Crane).

Finally, to conclude thi s general section, a quote from George

E. Polk which may be relevant in light of the abuse heaped on Rife
and Crane by the AMA, government, American Cancer Society , etc .
Keep in mind that onc e we got the cancer cure wo rking openly and
the story gra dually got known , we woul d be in a ve ry di ff erent
positio n for long-term l egal battle . Po lk:

'' I wa s a general patent attorney for, I believe,

the largest corporation in the wor ld. The fellow I
wa s most afraid of was the small i nven tor, fo r the
simple reason that if h e succeeded in litigation with
the company, the profits and damages he got were so
l arg e that we always d ealt with the small inventor if
we possibly coul d. So we do not g et the idea that the
sma ll inventor has not h i s resources. I f he has a good
i nvention, he will ge t something out o f it ultimately ,
and I would rather be in hi s place than the large
corpora tion he is buckin g .''
 6

Crane ' s Story

THE RIFE REPORT (RR) or THE CANCER CURE THAT WORKED : 50 YEARS
OF SUPPRESS I ON tells the tale of Roy Rife ' s cure for cancer and also
the scientif i c v alida t ion of p leomorphism which has continued to the
present time . Absent from RR is the story of his partner , John Crane.
In picking up the pieces of the original tale at the time John Crane
entered the picture, the author here will be outlining the problems
a nd possibilities involved in patenting the Frequency Instrument as
well as the microscope.

. In 1950 , John Crane met Roy Rife. After learning how Rife had
cured cancer in the 1930s but had seen his cure suppressed by the
AMA, Crane decided to commit h is energy , will and electronic and
mechanical k n owledge to bringi n g the cure for cancer to t he public .
Dr . Gruner of Can ada , who work ed with Rife in the ' 30s , provided
Crane with one of the original circuit designs for the Rife Ray Tube.
Crane also hired Verne Thomso n, an electronics expert with the San ·
Diego police force, to help construct the n e w Freque ncy Instruments.

Unfortunately , Rife had enlisted the h el p of electronic experts

in the ' 30s who never wrote down the details of the instruments .
Rife was unable to duplicate the marvels of his earlier Frequency
Instruments . The instruments were completed by Crane and Thompson
in 1953, but the test results were negative.

Nevertheless, Crane continued working to '' save '' Rife ' s historic
discoveries . In April 1953 , the first copyrighted material on the
cancer virus was published. In December 19 53 , Rife ' s description of
the cancer cure was completed under Crane ' s urging and insistence .
It was copyrighted in 1954 .

In 1954, Crane began corresponding with the National Cancer

Institute and other government ag encies concerning the Rife diagnos tic
and therapeutic instruments . In 1954, the Commi tt ee on Cancer Diagnosis
a nd Therapy of the National Research Council ''ev aluated'' the Rife
discoveries . The y concluded it couldn ' t work. No effort was made to
con tact Rife, Gruner, Couche or others who had witn ess ed actual cure s .
No physical inspection of the in struments wa s attempted. Elec tronic
healing was bureaucratically determined to be impossible. (In 1972,
Carl G. Baker,~ - D. , Direc tor of the National Ca~6 er Institute , ti sed
this super ficial 1954 evaluation to dismis s Cran e ' s and Ri fe ' s work
when asked for information by Congressman Bob Wilson of San Diego.
Millions d{ed and co ntinued to die because government and medical
au thorities were opposed to a fair, objective evaluation of the
e vidence.)

Wh ile workin g on the Frequency Instrume nt from 1954 to 1957 ,

Cra ne slowly be gan to get resu lt s . Each improvement brought hi m
closer to his goal curing cancer . Rif e con tinued t o aid him,
but in esse nce, the two me n were n o w work ing together and di sco verin g
toget her . Becau se neith er had the reso u rc es which we r e ava ilable
to Rif ei n the ' 30 s , building a high powered Ray Tube was impossi bl e .
But possibly Cra n e coul d do just as well or better . wi th a much
sma ller Frequency Instrume nt which attached to the body during
trea tment . Thi s is exactly what evo lved.
 7

In 1957, Crane made contact with Dr. Robert Stafford of Dayton,

Ohio. Stafford wa s interested in u sing the Frequency Inst rument in
both clinical treatment and new laboratory tests on mice. By November
19 57 , Stafford had 6 months of testing behind him. His initial
evaluation was positive. Of 4 persons with cancer, one made
"remarkable and unexpected improvement." The other three were treated
whilein a terminal stage. All died, but all obtained relief once the
treatment was initiated. Two were autopsied. The results showed
they had died from other causes. There was a "surpri sing paucity of
cancer cells ." Stafford also noted that of 33 patients treated for
a variety of ailments, none experienced any detrimental effects from
the · treatments.

· Stafford concluded his 6 months research with the following

summary:

''To date, i t appears that there is definite therapeutic

value in the eminations or pul sations from the Rife Machine.
While i t may be no panacea, as some might claim, I am
certain that i t has given relief to distressing symptoms
in some of my patients. Further, I feel ·that it h as
effected a clinical cure in several other cases. To date,
I have noted absolutely no harmfu l effect from the use of
this form of therapy. I feel that continued research
should and must be carried on in this field of physical
medicine."

Then, in 1958, Crane made his great breakthrough. He made

another in 1960, enabling hundreds of times more energy to b e
concentrated on the deadly virus. These methods have never been
published and are the heart of Crane 's patent claim.

By February 1958, Dr. Stafford in Dayton , Ohio had presented

his findings to the Executive Committee of the General Practice
Section of the Montgomery Country Medical Society o f the A.M.A.
The 8 doctors were impressed. Stafford began setting up a Research
Committee with Dayton's most influential doctors. Staffo rd concluded
his report to Cran e with the following!

''I feel very priviledged to have been allowed to

know of this wonderful instrument and of Dr. Rife's
remarkable achievements through your missionary efforts,
John. I shall feel well rewarded if I c an have th e
personal satisfaction of seeing the Montgomery Country
Medical Society accept this mode of therapy as an
additional wonder of the 20th century. ''

In · early · 1958, doctors in · s·al t ·La·ke C·i ty, Utah also began
using the Frequency In strument . But in May 1958, the Salt Lake County
Me di c al Board f o rced them to stop u s ing th e electron i c treatmen t .
One of the cancer patients broke down and "wept bitter ly whe n the
d o ct o r h a d t o t e ll him he could not c ontinue t h e t r e a t me n ts ." T he
s a me doc tor lat e r t old an as s oci a te in Sal t La k e Cit y th a t " i f h .i s
 8

own family had cancer that he would immediately purchase a machine

and useit on his own family. This would indicate how sold he must
be." The writer of the letter conclude d, ''Too many people have been
saying things that have aroused the ire of the medical profession
here.'' It was an old story -- a rerun of California in the late '30 s
when the medical profession suddenly saw their authority and incomes
threatened.

1958 also brought a hearing before the state of California

Public Health Department. A Frequency In strument was provided and
test·e d by the Palo Alto Detection Lab, the Kalbfeld Lab, the UCLA
Medical Lab and the San Diego Testing Lab. All reported it wa s
safe to use . Nevertheless, the AMA board under Director of Public
Health Dr. Malcolm Merrill declared it unsafe and banned it from
the market.

Still , despite the setback , Crane continued ~oward hi s goal.

By February 1959, Dr. Stafford in Dayton suggested that he, Stafford,
manufacture and distribute the Frequency Instruments in the Eastern
United States. He contacted a qualified electrical engineer,
obtained a patent attorney, and began cQ,,nvasing for venture capital .
Obviously, the results he was seeing in his hospital and with
experimental mice were convincing .

Crane decided to license the machines in order to prevent

doctors from changing the instrument and thus failing t o get results
-- Rife's experience with Dr. Yale and Hoyland being the example .
Since Crane already had completed a preliminary patent application
with a California patent attorney, he sent it to Dr . Stafford for
the Ohio patent attorney to examine. The two patent attorneys
agreed "al l was in order ."

However, they couldn't submit it until the "usefulness" of the

inve ntion could be shown. Thus, they he ld back work until enough
doctors and others experimenting with the different frequencies could
provide substantial evidence. With no organized medical, scientific
and laboratory involveme nt in the research -- as had existed in the
'30s -- Crane was forced to establish ''u sefulness'' with a terribly
difficult handicap. Opposition from the California Public Hea lth
Department and the expe rience in Salt Lake City , not to mention the
AMA assault in 1939, meant they _w ere in a Catch-22 situation regardin g
patenting.

So Crane leased his Frequency Instrument in order to build his

experimenia l b~se ~nd thus prove the usefulness of his invention.
The numbers of people who were being healed began t o mount. He slowly
gathered reports, testimonials and refined his procedures for training
new operators. As in 1938 , the breakout · point was nearing.
By 1960, Crane had written and copyrighted a manual which
explained how the Frequency Instrume nt was to be used in the
experimental treatme nt of various di seases and on diff ere nt parts of
th e body . In that year , thirty four instruments were built and
di s tribut e d . And the n the medical authorities struck.
 9

They raided Crane ' s office , took over $20,000 of privat e files ,
engineering data, research records and reports, machines and
Frequency Instruments, pictures off the walls, private letter s ,
invoices, tape recordings, and electronic parts -- all without a
search warrant .

They smashed all the research which had been put toge the r over
10 laborious y ea rs. As in 1939 , they visited the doctors who were
exp e~ imenting with the ma c hines and forced them to abondon them .
They also pre ssured ordinary citizens who had begun experimenting
on a · personal basis .

These visits were made by teams of investigators . "One woman

was scared so bad that she has been in a sanitarium driven entirely
out of her mind. Her husband cursed them out and told them to get
off his property and has threatened to exterminate them should they
return. His wife has undergone shock treatments and two months of
ho spitalization.''

The record s and materials seized were not allowed to b e used

by Crane in his own defense during his trial.

Roy Rife, almost 73 and incapable of suffering the abuse of

another trial at his age, went into hiding in Mexico. His deposition
was not permitted to be introduced at the trial. Neither were the
medical and scientific reports from the 1930s and 1940s . Nor were
medical reports from Dr. Stafford in Ohio. Dr. Couche 's letters
were also declared inadmissable. No medical or scientific repor t
which indicat ed the Freque ncy Instrument worked as represented was
permitted to b e introduced at the trial . Crane was left naked with
only the patients who h ad been cured or helped .

The trial was held in early 1961. After 24 days, and despite
the testimony of 14 patients who t old how the Frequency Instrument
cured ailments and· diseases which orthodox medicine could not alleviate,
Crane and two others were found guilty. The only medical opinion
offered by the State of California came from Dr. Paul Shea who had
been given the Frequency Instrument for 2 months . He admitted he
never tried the Frequendy Instrument on anything or made any tests
to eva luate it. He simply examined it and decid e d it had n o curative
powers and didn ' t lend itself to inve stiga tive use.

Also, and most disturbing, the foreman of the jury was an AMA
doctor. Everyone else wa s carefully screened to see that they had
no medical knowled~e, no electronic knowledge , .and· didn ' .t read any
newspapers supporting alternative healing . The v erdict wa s a
foregone conclus ion . Crane was sentenced to 10 years in jail.
Following appeals and dismissal of 2 of the 3 counts against him,
h e was releas e d after 3 y ea rs and 1 mo nth . But the cure for c ance1·
had b e en eff ecti v e ly sup pr es sed again .
 10

During the trial , J ames Hannibal, age 76, testified. Blind in

one eye, he ' d been treated by the Frequency In strumen t. After
several applications, hi s ca ta ract dissolved -- just as cataracts
h ad dissolved in many of Dr. Milbank Johnson ' s patients during the
1935 - 37 clinics. Other witnesses at Crane 's tria l testified to the
curi n g of chroni c bladder irri tat i on , the elimination of a throat
lump one -half of the size of an egg, and the disappearance of a 17
year growth the size of an egg on the spine . Also cured were fungus
growth s on hands , fissures in the anus, pyorrhea, arthritis ,
ulcerated colon , varicose veins, prostrate troubles, tumorous growth
over eyes , colitis, pains in the back , and heart attacks .

When Crane was released from prison, the cure for cancer was
in shambles . A weaker man might have thrown in the towel. But
Cran~ d .i dn't wai v er . · He started to fight all over again . With little
money and no legal h elp , h e fought a seemingly hopeless battle to
keep alive the discoveries which had been persecuted and denied
since the 1930s .

In October 1965 , Crane submitted an applica ti on to the California

Board of Public Health , seeking approval of the Frequency Instrument .
Rife was back from Mexico but hanging in the backg~ound. The applica-
tion was made in the name of Rife Virus Microscope Institute of
which John Crane wa s the owner . On November 17, 1965, the Department
of Public Health replied that Crane had not shown that the device was
safe or '' effective in use.'' Again, Crane could not prove to the
auth orities that the Frequency Instrument ' s ''usefulness'' was a fact.
While the reports from the 1930s and the limited research in the late
1950s c learly d emonstrated extraordinary healing results had occurred,
without living auth orities willing to put their experti se and medical
licenses on the line, the state officials couldn ' t approve it. But
every time doctors, researchers and ordinary citizens got to the
point where the validat i on of '' usefulness'' seemed near, the medical
authorities quashed further research. Crane and Rife could not
patent their invention wi thout proving ''usefulness." They couldn ' t
market it without proving '' usefulness. '' They couldn ' t interest
fi nancial men and researchers ~ithout ''usefulness .'' And the medical
authorities and public officials ' deadly game had its death tol l also
as hundreds · of thou~ands annua lly died from cancer while many more
suffered from chronic diseases which als o could not be treated by
the Rife-Crane discoveries.

Crane attempted to re spond to the Depa rtment of Health ' s requ est
for proof of '' u se fuln e ss. '' Dr. Charles W. Bunner, a chiropractor, wa s
one of the men who provided a statement. The .result? The Qepartment
of He al th forbade him from using hi s Frequency' Instrument and then
a court ordered it '' des£royed .'' The second man to provide a statement
attesting to the Frequency Instrument's effectiveness was Dr. Les
Drown, also a chiropractor . An employee of the American Cancer
Society wa s soon sent to his office to entrap him. He was f orced
to '' sign over '' his Frequency Instrume nt or go to jail.
 11

Rife and Crane were intending to pate nt the i r joint microscop e

in the late 1950s along with the Frequency Instrument. A microscope
diagra m for patenting purposes wa s dra fte d with both names listed
as inventors. (A photocopy is include d in the Appendix to this
report.) Rife also was intending to patent his Universal Microscope.
The assault on the cancer cure in 196 0 disrupted their plans. Without
being able to s how ''usefulness, '' Rife and Crane could not patent
their discoveries . The actions by the defenders of medical orthodoxy
stymied every attempt Rife and Crane made to bring the cure for cancer
to the general public.

Rife had obtai ned a patent on a microscope lamp in 1929, but

that. was before the threat he represented to the orthodox medical
(and scientific) es tablishments was recognized. By the middle and
late '60s, Rife had witne ssed or learned about (1) the spectacle of
the AMA crushing his discoveries in 1939 and forcing doctors to
abandon them even when numerous cancer cures were on record; (2)
the mysterious death of Dr. Milbank Johnson in 1944, apparently just
when he was prepared to make an announcement about cancer being
curable; (3) the hopeful revitalization of the 1950s under Crane's
direction only to fail when crushed in the 1960 travesty of justice
whe n all research was confiscated and scientific reports were
forbidden to be introduced at the trial; (4) the mid-1960s attempt
at legitimization and how the medical authoritie s again had pres sured
researchers and health practitioners to quit .

Rife would b e BO years old in May 1968. He had fought his last
war. He knew he was unlikely to see his Frequency Instruments or
hi s microscopes used to heal virus-caused diseases . And he was
uncertain about the protracted exchanges with the Patent Office
which lay ahead , especially when the issue of " usefulness " was a
Catch-22 situation for whic h there was no solutio n. Medical treatme nt
had to be approved by medical and sc ien tific authorit ies. Every
time such men appeared and offere d Rife a nd Cra n e hel p , the medical
po wer s crushed them or forced them to give u p Ri fe - associated researc h
or tre a tment.

So on March 4, 1968, Royal R. Rife signed o wner s hip of his

microscope to John Cr a ne, indicating th at he inte nded to pate nt it
and tha t John Crane would own the ri gh ts. The Frequency Instrume nt s
Rife considered joint inventions because of all the original wo rk
bot h Rife and Crane h a d done on them .

. But Rife didn't apply for the micro scope patent. He was old
and at le as t had legally ma de hi s wi s he s known. Hi s executors could
fight that war if Crane ' s pate nt applications pro ved successful . All
hi s cancer-curing rights were assigned to John Crane.

Unfortunately, Crane ' s patent applica ti o ns were not succes s fu l .

Cr a ne appli e d for a microscope patent an d a se parate Freq u ency
In st rume n t pat e n t (along with other in v e ntion s ) i n 1969. Corre spo n -
d ence a nd amended applicat i ons bou nc ed back a11d forth until 1973 .
At on e point , the Pat e nt Office admitted to Crane 's Co ngress man
th a t i t had t a ken them a year t o re sponcl to o ne of Cran e ' s " inquiry
of status " letters .
 12

Crane saw a familiar pattern. He suspected high-level pre s s ure

although the history of the Patent Office is an extremely good one
as far as ethical conduct is concerned .

Nevertheless, given that Crane's patent application clearly

described a cli nically successful cure for cancer using a breakthrough
technology supported by top scientists and doctors in the 1930s , the
Patent Office's ''business-as-usual'' procedu r es with John Crane durin g
1969-1973 certainly leaves much to b e desired. ''A War on Cancer ''
ha d been declared by President Nixon . Hundreds of thousands of
Americans were dying annually and even more being diagnosed as
having cancer. Yet , no one in the Patent Office could pick up a
phone, send a telegram , or alert public official s . Or perhaps they
d~d. Perhaps the National Cancer Institute officials checked their
files and told the Patent Office to ignore the claims. They had
been dismissed. Perhaps a Patent Officer examiner did exercise
responsibility in a quiet way and wa s instructed (falsely) that this
Rife-Crane matter was not worth any serious attention.

In any case, no Patent Office examiner ever bothered to pick up

a phone, mail a telegram or pursue the larger issue with John Crane.
Yet Patent Office examiners have ''informal'' meetings with patent
attorneys representing clients all the time ~- in order to clear up
difficulties and come to mutual agreements. But with Crane and
the cure for cancer , no suc h initiative took place -- even though
hundreds of thousands of Americans were dying and a declared national
policy to cure cancer had been announced by the President o f the
United States.

Instead, the Patent Office recommended that Crane obtain the

services of a regis tered patent attorney. Crane had poured t housands
of dollars into de fendin g himself, fighting a court system h e perceived
as corrupt (quite rightly in his case), and didn ' t have the mone y f o r
a pa tent atto rne y .

Again , the powers that served orthodox medi ca l treatme nt, faili ng
though they we re in cancer treatment, seemed to h a ve won.

Roy Rif e died in 1972.

In 1987, the questi o n is, can justice be realiz e d at l o n g la s t?

Ca n the Freque ncy Instruments be used to cure canc er? Can t h e
micro scope b e use d to d etermine the fr e quency o f the AIDS viru s in
order that the virus be destroyed electronically ? Can a n e w pate n t
a~plication or a legal action right the obvious wrongs whi ch have
b ee n done so that Rife and Crane finally can be given some small
rec ognition for the fight they have f ought against overwhe lming
igno rance and seif ~int erests opposed to the public's well-be ing ?
 13

The four primary areas of patenting which concern us seem to

be:

1. Prior publishi ng
2. Prior sa l e
3. ''U se fuln ess ''
4. Rif e ' s co-status
5. Crane' s oath
6. Special appeal

An outline of the issues ca n be grasped from the followin g

desc.riptions:

1. Prior publishing . ''The law provides that the i nventor is

not entitled to a patent if the invention has be e n describe d in a
printed publi ca tio n a nywhere in the wor ld more than a y ear before
his patent application is filed." (Q & A About Pate nts, U.S. Patent
Office)

" Any disclosure, whe ther in a scientific magazine , book , or

thesis, i s sufficient to constitute a printed publi ca tio n. The
description must, however , be complete wi th respect to t h e invention
that i t di scloses , and a mere hint or suggesti on may not amo unt to
anticipation." (Copyri g hts, Patents & Tradema rk s , Wincer & Mandell)

2. Prior sale. ''A valid patent may not be obtained if the

invention wa s in public use or o n sale in thi s country for more
than one y e ar pri o r to the fi l i ng of your pate nt application ." (Q &
A About Patents)

3. '' Usefulne ss .'' ''A patent will not be granted on a usel e s s

device . . . or on a machine wh i ch serves n o useful purpose ." (Q &
A About Patents)

4. Rife's co- status . ''If each had a shar e in the ide as formin g
the invention, they a re joint inventors an d a p aten t will be issu e d
to them jointly on the basi s of a proper patent application filed by
them join tly ."
•

''May a patent be granted if an inventor dies before filin g h is

applic a tion? Ye s , the a pplication may be filed by the i nve ntor ' s
executo r or administrator.'' (Q & A Abo u t Patents)

5. Crane 's Oath . '' This s ection of the spe cification require s
you by law t o make an oath or declaration th at to your knowledge your
invention wa s n ever known or used befo re, pa,tented , or described in
any pr in t ed publi cation , i n public use or on sale mo re than one y e ar
pri o r to y o ur app lic a ti o n , and that y o u ha ve n ev e r befo re fil e d a
pat e nt applic a ti o n on this particular inve nt i on. " (Id ea s, In ve n tio n s
& Pa te n ts, Ab e r n a t h y & Kn i pe )
 14

6 . Special Appeal. ''If you do not reply within the time

period specified in the action, your application will be abandoned
by the Patent Off ice and your patent application will no longer be
pending, unless you can prove to the Commissioner of Patents that
your failure to file a response was unavoidable because of a
legitimate reason . (Abernathy & Knipe)

Obviously , any new application -- even if based on the prior

patent application -- will have to address prior publishing, prior
sale, Rife ' s co-status, etc . Not only will the inevitable "prior
art '' cited by the Patent Office to reject the claim have to be
carefully offset (Prior art is recorde d earlier inventions), but
the automatic rejection made likely by the prior publication and
prior sale will have to be addressed and successfully overcome.
Usefulness , of course , is a special situation . But here is the
two-edged s word. The usefulness of the inventions has to be argued.
But it was the suppression which not only prevented ' usefulness from
being established years ago , but which was responsible for any
necessary prior publishing and prior sale . It can be argued that
prior publishing did not disclose critical technical features and
that prior sale (leasing) was in fact essential experimentation to
establish usefulness.
However, it seems that if patenting is attempted (which the
author believes ought to be done) , substantial legal (and political)
effort will be required. A standard Patent Off ice approach seems
to be an exercise doomed to fail for any number of r e asons .

In conclusion, in making the argument for a patent grant to

Rife and Crane -- whether it be through the Patent Office , the courts
or the legislature -- it seems appropriate that the ab iding principle
of the various Patent Acts in American history be cited. This abiding
principle is generally recognized to be J ef f erson ' s philosophy that
''ingenuity should receive a liberal encouragement . " Ingenuity has
no meaning if Rife and Crane are denied r ecogn ition because of a
technical ruling when the authority to grant such recogniti on is
available -- either directly from the Patent Office , via judicial
decision, or as the result of a legislative action . To ·deny Rife
and Crane could be ·h is torically seen, because of the specific
governmental abuses in this case , t o sanction such abuses . Thus, it
ciould serve to discourage ·future inventors who would perceive special
interests as being in the control towe r . Such a result wou ld not be
in the nation ' s long-term interest or in resonance with America ' s
underlying democratic principles .
 APPENDIX

A. Crane ' s letter to Dr. Robert Stafford Oct 1958 (2 pages) 16-17
B. Crane ' s letter to Dr. Stafford Nov 1958 (2 pages) 18-lBA
C. Dr . Stafford ' s letter to Crane Feb 1959 19
D. Crane ' s letter to Dr. Stafford Mar 1959 20
E. Dr . Stafford's letter to Crane Apr 1959 21
F. Crane ' s letter to Dr. Stafford Apr 1959 22
G. Crane's letter to Dr. Stafford Jul 1959 23
H. Rife and Crane letter to Dr Stafford Aug 1959 24
I. pr . Stafford's letter to Earl Steiff May 1960 25
J . Dr . Chapman ' s enrollment application Sep 1 960 26
K. Contract to use Frequency I n strument (3 pages) 27-29
L. New Device Application Oct 1965 (2 pages - 1 missing) 30-31
M. List of supporting documents for new application 32
N. Department of Publ i c Health response Nov 1965 33
O. Receipt of statements by Dr Drown and Dr . Bunner 34
P. Crane letter to Director of Public Health Mar 1966 35
Q. Attempt to retrieve Utah Frequency Instrument May 1966 36
R. Attempt to interest Institute for Cancer Research May 1966 37
S. AMA position Sep 1967 (2 pages) 38-39
T. National Cancer Institute position Mar 1972 40

Pate nts

u. Rife ' s 1929 patent (2 pages) 41-42

v. Rife ' s 1929 design for microscope lamp 43
w. Rife ' s and Crane ' s Joint Microscope Design 44
x. Rife ' s assignment to Crane March 1968 45
Y. Di agram of Frequency In s trument I 46
z. fu N(N' 8b Po-.~jdV\.. 0- Vr-c._~~ l.uL .1~ fcav1cer "'#'7-- 5(7
 APPEN DI X A

AoBc-r<-7?, $r~~
Bob s~rord1 !"l , P ~ October 22, 1958
22 Deshler Place
Dayton 51 Ohio
Dear Bob
I have been advised by a local group ot research doctors that the
tost set up tor provsng out the instruments on rats hinges on a
certiried biopsy by a pathologist before treatments am at"ter treatments
wen the rats are well, they ab.0111 d be k1 J led and another biopsy taken
for each rat. The b1ops7 should be numbered and 1dentir1ed on each
~ llhich the7 tell me is the most universally acoepted evidence
tliitcan be obtained. I ho~ that you vill toll.ow this procedure 3.lso
on at. least 6 rats with one control_. and havin& a pathologist to "sign
ott the slides" betore and arter. (and I m.,v sure -;.,onld like' to have.
those . slides.) •

There 111 another element Bob 'Which ma~ have a great··dea1 ot· 1n.1"1uence
on your test results and I'm going to propose it tor yeur tube tests1
BU3' an RF Power Meter Kit trom Heath • Heathk1 t PM-1 at $14.95"i. Leave thf
antenna ott aa shmm 1n the enclosed picture and you vill be .able to
measure the direction and intensity ot the Oleatrostatic spaft' rield
coming out or your applicator tube ot the Frequency Inst~ument.·._, Many
times treatments are given with the torce trom the tube '-ctl1aJl7 missing
the patient. With this little inatr•nnent you can actuall\1 check this
yourselt before using the F1eqency Instr11ment on the rat$ beoause\ every
tube tranm1t:s this field in a dirferent direction. I w\Jld suggea·t that
you place this RF Power Meter approximate~ 10 inches away trom the
angt1lar electrode or th• applicator tube and turn ,the volume control
down until the maxtmma output ot the FreqUenc7 Instr•:rment can still be
read on the RF Powr Meter PM-l - than adjust the FreqUency Instrument
/. vith the tt1n1ng knob at th• right top 'Which controls your 24-00 E
readinc and then rorget it - and the ~ knob setting that gives you the
mAx1 mm intensity or the charge Of the Space f'ieJ.4 from your appllca tor
tube Wicb can then be read dil'ec~ on your nev R!' Power Meter PM-1.
Leave this knob 1n th• maxi•n••m field 1nuns1t7 setting throughout all or
your otrutr dial settings idlich you vUl read corre-Ctly on the electron
counter. Your rasu1ta should shov an amazing 1mpro'fl9ment.
I am working on soma plastic h•ndles that v1.ll be shipped with the tube,
this v1ll mean another weeks del&J". The handles are. completed now and
spectal connections w1ll be 1nstal led w1 th shielded high voltage wire.
I have ~n doing some th1nldng about the e.lectrodas 'Which w use dil70ct
to the body- am I tbi nk they are too amaJ 1 - larger ones
would let WI use 1!10re current tor aven 'batter results.

-- -·

l6
 1\1 · 1· 1·:1J 111 ,\: /\ ( 2110
µ ay e)

fi7<C7+ , IF
8 C&/l<o o es- w 1//1
OF _s o/V

/7C-"1< 1.l-;47J w ~ C:Ot// D u_re- rl

e:t-cc.. r;e CJL) €- ~.D
/f
~~-e::.-r -A -
Fof?- pfl-r1~m

J 0, wl5H ,)/'cv
£~c 17<o£Jt:....s

4/7/ . 'o

e:-ven/ J-1-Th/ e- ,, o F / / /IV;.,,,, /J7f/ / /V..// 1 v' DuA-t_~

;#· ~:R-/A~A/ /J·R£::71 l-s ( 1 - o A ~/'/v.vc+I
L 1Ke- A- J.> c::~/ /i.~rr u .rc-::s- /'. o ~ e: 111 _r
,!-i_....,

p;t+z-s-E- -;rz::=7-/1 t·-' 11r1 p-v.R ~ r7 -r.nµ ~

jV7 1:·7 n-t__ ~7. 1.~- -,.-: - .~ - :,,:: o /) 'C·;~ 1 -;J-/7 /1/" 5 ~ E rs oF-
C>/./ c / - c:.
Iµ T 1-1 c- C -71 ::5-C ,., ;..-.-.
/t-1 ;r4 ;Y lJ...)t::;- 'f /) ·f-::: /) 1 .. / ;-=: L-
/o ~Vt::- . n..,/1 Yl/1- t / , , ._, _ ~ ?- P- f9V T

T 1-1-;< 6 (.) 6-4- I;.+-£-- /1 F-~7+-

t !:>. Fft,c:~ ,
- , /,,vf"T,R,,

.-·/ •
/-' F77C&
I/./ S rf?, -;-·o r 7< c-·c::z -
/,,V j 7 x, w tJ A I /.Lf\ v E ? 1 <./ .
_yov pv. A '/
1_,_.1 11- L- °13 C KC·? / <"J .V/- I
'.-:- i> C " -' / / A--c_ ,

_... . ..
I l
(.. 1 ~ (, )
 APPEKDIX B

19 ?-Iov 5"8
Dear Bob
I am sure glad to hear of the rat tests and if they are still alive
a!'ter 50 days we Will be e.mn%ed . ourselves. Very little work has been
accomplished with the leukemia virus as Rife specialized on carcinoma
virus ru1d sucoroa virus. or the 50 to 60 odd types Rife found that the
same virus was the culprit and the frequencies which you now have kilJ
these vit'1.is. J.'arsh t'eported some success ·Ji th leukemia patients in SaJ
Lake City and we received a letter from a woman who had gained weight
erv' recovered her strength but how she is now I couldn't say.
Recent tre ~ t!pent or a \IO~.an with a serious case of fissures - heIZ:toro·
and pi1es has succombed to the Tube type frequency instrument in
combination with the diather.ny instrument. This is the second case th
we have cleared up. The woman was scheduled for an op~ration and in
severe pain. The pain seemed to vanish after the 2nd c.
I believe it is extretiely important to have an exact setting within
; + or - one tt1.t~ cps. A resench proposa1 was made on this point
for funds but was denied. I wanted to go farther into this problem
because we now have electron counters that w11l read down to 4 dec1In•
ot a cps such as 2128.0123 etc. Further research can only tell us
exactly what the 11Cr1tical Frequency Tolerances" will be. Var:ring th•
cps after your treatment or three minutes may be very beneficial an:l
it wou1d serve as added insurance toward the results attained I'm su
Another means or allowing the patient to handle higher current input
might be novocain such as the dentist uses to ~omentarily dise~gage
the nerves. A milliamp meter should be used to avoid go1ng over 100
millia.mps as I think t.li:it is about as high as can be safely attainee
but again w have no research on this point and much greater power
may be used with great effect by this method. The electrocution of
bacteria, virus, and fungi by this :nethod is entirely in its 1nfanc:
Several of these instruments :l!B.Y be employed simultaneocsly on diff
body area~ but I believe the total current should be ceasured and
controlled. Your jelly sotinds like an insulator to me ·and the h1ghe
input may be erroneous. I think area increase is more of an answer
Since silver is the best cor.ductor ;re have used copper and silver r
same. kl.11minum would work OK or any othe.r gooo conductor should be
s a tisfactory. ·

18
 /\ l' l 'ENl> .I X I~ (2 n d 1)a(Je)

P.egarding ?·!rs. B::i.r1durf\ - I feel that your distance fro m the cervix
to the back of the neck is too f:,.r. I woul:i sur.e~s t that y0u endeavor to
keep the electrodes closer toe:"! tl1er s~y w1 tl1in 8 incl1es - firs t treat thE
liver and or cervix Ari>a n11r.l th'lrt go up anll ~i;)tti treat t.~a ;j:~~lf, aorta are~ .
This sl1ould give a mor'3 cor1c81ttrRted currer1t flow in t he affected areas
and to my meager thinking - g.t VA you bat tar results ••\n clactric field may( ]
be dividec u, into linas of fore~. (2) each line terminates at a positive
charge on one end and a negntivs charge on the otl1cr.(J) the lines t1i.rough·
out the field, coincide witl1 the direc tion or tl1e electric strass.l4) the
lines behave as thoueh they were nnde or stratched elastic, al'.·1 ays t e ndine
to contract nnd bring t ogeth~r the negative and positive charges.{5) a line
·o r force between two condt1ct111 ~ ~\lrfaces r.nlst al,,.rays meet the co11duct1ng
surface ~~~~Ji~P.X perpendicularly . This must be so froa the very natur9
of the assumed static c onditions . If a line of force enterod or left a
conductiug 3u.rface r.. t any otl1er ar1gle than normal, 1 t viould have a t:'lilgenti:
component at the surface \·1l11.cl1 \oTO\tld cause the rr:0vement of c!1ari;es within
the conductor. 'll1is •..Joulrl cor1!-Jtitt>tl3 a continuous electric current nnd , sin
currents do not flow alor>P, t:h~ s11rface of t he con9uc~or in an el ectric fiel•
in a static syztc.1:1 t}1e jtlt,ct.1.on of the line of forco am the surface r.iust
7
be a ri ght angle. \the pictur~ of the force lines I drew ~ould app:y here)
The elect~ostatic field 1.s stronf : ~r when the electrodes are closer tobether
To increase the pow~r <i ~r.i :~ l l ~"'J>lifit?r or the audio type ":ould i.:>e necessar
with the henthkit in3trurner1t. 'fl1is ar,ain is a matter for further research.

To answer tl1~ questi o1t nl:r.1111: 111.tr:i.vl,>lf'Jt liet1t frnn ·the ne,., or o lr\ l)ul.b;
An analysis of tt1i!': lir,J1 t; ~ 1n.!"1 m ~ ' ' ~ ,,•:1. th~ Tiilc;er F-4 qu.artz spac tro gr n l't1
which 1ndica ted the ligl1 t nn'l ;:J1° t'roduction thereof to be in th e vi ~ i hle
re gion o~ . from 4000 A tc> 6 '.)t>Oy1 Ar1gs t:ro1:is. The ultra violet e~tends f:r-ur.1
4 000 A on <lown to 200C' A C' r.<\ 1:1111, t l~ wl1~ro our chart ends . ~one sl1 i: l1 t
overlap mal" cccl1r irt ti \~ 1 1 !..'(~' > ,•, .'ll"C'J;\ t>ut it \·T0\1ld be so sligt1~ that - I d ot1t;
if any effect \·101.11~1 tin n 0. l:len ::"O l : l~. (ll1.ly ordinory visible 11 (;ht is er.cnltt <?d
due to th~ r.ng d1~~! 1~ r 1.~ ? ·f.11 l:l 1n f;1 1hn. ~ Tl1e F.F b ti s b~!?n re ted o t 33C• v 0l t!l
using a Hewlett P 2.t~lr ;. 1· r 1 :i1" ~ 1 1°1 11 11111, "1:ltl1 C4. morleJ. 4?3fl P.r. crip~. c:tt:~· 1 \J-;~ . ·J~
having a 100 to 1 rt.' tl c'; 1:110 l r11r"' 11::-1.•c g l-1l tllcut tl1n di\•i1er is 1 0 ~ '?g c- brns
(D . C . ); with tl1e cC!p':\cil;:r cl.1.v.lrl 0 r :I. I: i.s lOOX greater . No loa dinf; c f tl1e:i
instrllrlAnt occt-.r~ ctu <:! t o t~ 1 l ~ r.1:"'' ~ 1.:r !'~a nt , 3.S J1 . d ~f>\l 1.J:r a lacJc o f
detectablo cha ng':? o f at1d io -0 11.::i111.t irt a ro<lJo r0cA1ver. ~o :r.-r "lr s or i c1r11z1
radiation ar9 emitted by t 110 t; 11 b<.> ~-1! 1 1113 the J iscl11Lrge is t ~k in g p l~ ce .
These measurements hRve D€~n r1~<.l~ c .l osq to the r.lass env~lope of tl1~ t11be
both vi th a nuclear. morl'?l :;GJ.J. c;eig_er'.'"t-1uller Survt:?y t-; '3t~r, as well. as a
sensitive Lauritsen el ec tr o ~~op~ of' t11e integrating t:r>e. 1~o r~d1at1 0 11
above backgroun~ was detectff.f.ed by either of these two · instr~cnts.
Sincerely
I I /""
-=:;;::;,I-;·' ;... ' - "'( .. ,
John C:-ane

If!/\
 APPENDIX C
ROB E R T P. STA l"l"ORO , M . O.
THOMAS a. OBW A L O, M. O .
O E ORO E W . MARK US, M. O .
'702 •ALCM AVCNUC
23 Febn:al"'J 1959
DAYTON 6, OHIO

!ir. John Crane

Life Lab , Inc,
San Diego, California

Dear John,

Pursuant to my inquiry in my last letter r egarding possible marruf acturing

a~ reernents, I would like to know if you would consider · letting me handle the
.;;astern Vi vision for the purpose of manufacturing anci distributing the Rife
raachine . ~his mi{;i1t be done on a licensing basis, where ,.,e would ;>ay to Life
Lab ' a stipulated royalty on each raachine sold, or on some percenta.£e distribution
of the profits. Perhaps you have some other plan for equitable rer:ru.neration
due you for the use of your patents and e fforts ~hich you mibht wish us to consider .

i·iy f riend; Harold Leland, and I are interested in developing a manufc:cturinf?

compa.ey to handle this project east of the I-lississippi River; providing
satisfactory arrangements are trorked out bett•een us and Life Lab , Inc .
Harold Lela."ld is an excellent electrical engineer and has had mc:.ny years of
experience t•orking closely with the management of one of Da;rton 1 s successful
marrufacturing companies. He is the man who did the caljbr ~ting of our machines
on his 11 scope" at the factory. ~e is also the man who knows sol.onoids from
A to Z. 'f his will help us in perfecting t he dialings of our present machine.
Also, throut~h his past experiences, he cou.ld help guide us into proper channels
to assist. us in protecting ot:..r ~ork . Along this line, Harold ·would like to know
what patents are pending and applied for as well as the description of these
patents, regarding the Rife machine and its uses.

If satisfactory tenas could be a.freed upon between us, it seens to ~e that

such a '•orking arrangrnent t-1ould enhance the p r omulgation of this net• medical
science araong the medical profession. I trul.y believe this thing is big
enough and ha s enough potenti al to a1 lot<t at least this much di versification
of capital . Your experience in t:1e vie stern Di vision could guide a."'ld help us,
and likel-ri.se, \.1e ~•ould share our experiences, developnents, anct refiner.tents
in technique 'I-Tith you. Such a.'1 arrangment \.1ould not nea.'1 \teak~ess t hrou::.c~
cleavage; but rather, strength throu~h division. Please let me k~ow what you
folks out there think about these proposals.

Robert ? , Staffor d , ii. D.

19
 APPENDIX D

Robert P. Stafford, M.D.

Dear Bob, March 6, 1959
It is heartening indeed to read of your interest in the eastern
market and your requeat mar well become your desire and reward. Since
this instrument is a specialty item, legal counsel say-s that we sho11Jd
require a 10% royalty on the gross 1.ncome and that all future patents
related to the instrument 'orould be assigned to us. It these major terms
are sa-tistactory to you and vhomever you care to 1nclude1 we will have
our attorney- draw up a preljminary draft for your approval..
We will or course wlcome such an outstanding engineer as Harold
Leland and a great deal. or expert ta1ent will be needed 1n the various
tields encountered. The design ot tha t1rst production instrument 1s now
ot importance and should be perfected below 10 KC to avoid FCC
qualUicatiODJ this can be accomplished but the coil must be used 1n the
center ror a little while longer.
It haa been our contjn>1Sng thought that the 1n.struments should be leased
and not sold s1m1 lar to I81'f procedure because the instrument must be ·
checked periodically ror correct output, tubes, etc. Doctors have had a
tendency- to change th61r instruments in the past and then they- do not
work right am w have experienced this maey times and this must be
el1mSnated. Leasing wot1ld provide a monthly income on each instrument
wb1ch is better tor the doctor as he can write it orr on his income tax
am better tor ~ to maintain our control ot the instrument. The original
cost can be eliminated by 1nsta1lat1on costs or license tee costs or
absorbed by renta1 tees. Older units could be re)laced periodically and
shipped overseas for foreign markets.
It may- be that your nev manut"acturing company could turn out to be
a division or Lire Lab operating indepezxlently 1n th4 area designated.
The franchise tor the area east ot the Mississippi in the u.s. exclusivel~
will be or great value. Whetlj.er we were to aaaept a roya1 tr or a
percentage distribution, the value would be the same as tll8llt1oned above.
At this time a great deal ot tlex1bil1ty exists and we will welcome
four acceptance ot these terms and let ua know your further comments.

Verr truly yours,

·· Enclosure1 Patent appl1eat1on

{Please return 1n one month)
•

, .

20
 APPENDIX E
ROBERT P. l!ITAP'P'CRO, M. O.
THOMAS Cl. OSWALD, M. O.
•
CIEDRCIE W. MARKUS, M. O.
"702 8A~l:M AVl:NUI:
20 _'_:)ril 1959
\ CAYTON 6, OHID
.~r .Jo:in Crane
Life Lab, Inc . ,
h 2~6 ? eooer J rive,
•
Sa~ Jie~o 5, Galifor!'lia

Dear Joh.'1,

iiarold :elc...."1.d ar1c I h o.;.ve been studying the t1a.ny facets of establisn=ii; '3
conpc:.ni for tl1e ;iurpose of manuf actorii1g a!:c distribut.; :!f; t '.1e :::ife =·!adulated
•
Radio- f r eq_tle:icy· '.:'r a!'lsr'litter. I 1 ~n St!re ~rou are 1-rell a\-:are o~ t he pro·olems
"t-:iic i1 co:1front us alont; or;_:;W', izational lines of this nature . ~ Iarold is :-:.ore
e:-:;>erie:lced i!1 t ~1esP. :-:iatters than I am, si · ce ~le is &ssociated i:-;-i th a local
r:1a=iuf e.ctori!1r- ., at :.. > r esent .
........ comoan~r

:[e
oatent attorr~e-1
...

h2_i;e consulted :1ar :Jld 1 s lc.\~:"er, r::.r .· :·_:yTes Stoddard, 1-rho is ~lso a reG"j.stered
. :':r 3toddard ~c:is exa.":lined fo r us· ,rour 1eti tion to the r . S .
•
• v ~

?ate=it O:'fice . :le feels t:-tat all is in or der, br.t !1e SU[ [ested that 1-;e ob tain
your permissio::1 to revie'!v the file ~-rr~pne r anc~ contents rege:rdin§; the patent
oendi!"lgs on t :·:e rl.ife rnachine . Since tiese natters are of Sl:ch tech11i.cal
natur e , • su;~f;ested t hat ~-Ir . Stoddard ·11rite to ~,rour attorne:-r, iir ·~ald-:·;ell,
so t ~~t tilis i~1atte r ca'.l be -vrorked ou t at t i1e earliest oossible n.onent .
_:l_s . ~r . Stoc:dard su~: gested, it •,.iould be 1nse for all of 1ts- :;ro1~ folks i!'l
•
~alif orri.a, as ~-iell as for us here i 2.1 Dayton - to be rea::>onc.bly sure t:ic.t
t.ie can ·oe protected b:y- pat ents in tc1e futur e use of this fonn of en::rgy
on vir.!ses a::.d bacter ia befor e 1-.Te i:"lvest t ;1e necessary capital to engineer
~n~ ~roduce a practic~l instn;ment.

~s you re~uested , ! shall r etur n your Petiti on to t~e ?otent Office b~­
•
re~isteded mail in t!1e :1ext fet.,r days . 2.lso , I an enclosi=i[ a si.i-:1'.nar..1 ::-e:;ort
o: t i1e J.t:.t. .:.:cperinent. The res~lts of t :u s prelirli~ 1::~~.. e::-:peri:"l.e:it have
;:i ve".1 us a :_~ood foot- hold i:i the door of local r1edic ; .l interest. I'm still
tr-Ji:-i; to fiE;li.re Ol4t iv'."'.ere 1~e can get t~e needed :-.5, 000 .oo to 9roceed 't-~ t l1
t~1e .1ext phase of laborato:::.:- e::qlerimentation. -·01·re•.rer, Jo::.n, I ;~c.~.re si:1cere
:·ai t:i ti~t vle s hall co:iti!l'l.:.e to make progr ess 1n t h this :'orn of tr..e r~ p:r,
•
if ~·re c:.re co :~scientious , honest, a::.c stendf .:?.st . I sh ~ll l T:. te ;.:~. :: 4 n r e s;gr c; :i.g
tie details o f for:'Ung our compc..ny ~ere, :::.s soo:i ::'. s t he "Jl'.ta~t :1roblens
are cleared un . ..'.6ain, .Jo:1n, I •·1.:.."1.t to thank you fo r ::tour '.)TO-:-:l?t"'.'less ~!:d
6ene r~si t~r in offer ing to license :1.s.r'.Jld e.nd :ne to ~;o:-k ~ri th you i:-t t:-i.i s area .

Sincerel~.. ::-ours,
•
•
,_,ob .::>- t ar.
'Q ... or d •
,Ct

•
I
l
•

21 •
• APPENDIX F

April 23, 195'9

•
Dear Bob,
Thank you tor your repori on electron tberap1 as an entirely
new tacet of research. Bob - on the next tests, I hope thaJI
• you will tr1 some carcinoma tr sarcoma and I feel sw-e that
your results will be better. We have in the past encouraged
trying almost everTtbing and Rita has told me many times
"Wh7 not tr7 ·it on something that it has been proven out on"I
It is d1f1'1cult 1ndae4 to realize the t:2me and effort which
went 1n to securing the frequencies and I will not be happ7
• until tha whole phase o~ the research with the microscopes
is run thru aga1n so a8 to determ1na the trequenc1 tolerances
which to me is the ke7 that will 11nl ock cri t1ca1 design
secrets ot our :f'uiure instruments. ·
I have contacted Caldwell and you have our permission to
• review the tile wrapper and contents. Please have Mr. Stoddard
writ• tot
Conrad c. Caldwell
3993 3oth St
San Diego t Ca1U •
we are now tr71zig to tigure out hov we can get ;oo,ooo ... to
• build a new research lab to carr7 on Rife•s work. We have
several local capitalists interested and we hope before too
long to have this move accomplished. I can ass·u re you that
should this take place, 5' G's ot this tund will be yours.
There is a1so some errort being made to treat Sec. John Foster
Dulles. PowerruJ. political. contacts are now being used to ef'f'ect
• this end but the pressure is undoubtabl.7 grent. In ~ event,
some active interest ma7 be the outcome.
tictice ot a medical electronic display 1n Paris, France this
June is ot passing interest. We have decidecl not to submit
an7 material this rear as l) it might rock the boat vi.th your
• efforts there aJ'1d 2) we d6n't want the Russians to get ahold ot it •
Again lat us bow our heads 1n praise ror your fine research work
on electron therapy. Did you ever receive the 21+11 enlargement
of thr Universal. Microscope and a second pre-release
report on "El.eatron Therap~" ?? with photos •
•

22
•
 AP PENDIX G
J11ly 1, 1959
421+(, Pepper Drive
San Diego 5, Calif. Page 1 or 2

Dear Bob,
Received the tube that you shipped in good shape. I was surprised
to find the pl.astic holders also and if' you would like these
returned, I will ship them to yoUJ I would suggest however, that
you mike up the diameter ot the glass to be sure that they wtl..l
fit as these tubes are aJl hand made. If a larger inside diameter
is necessary for the plastic, I w1ll attempt to bore them out to
fit before sending them back to you. I have also des1gne1 a new
a:J.1nnim1m ring Wich goes over the rubber insulators and holds them
1n place to make a 111cre f1n1sl1ed looking job out; of the tube plastic
holders am two metal rings go aro11rrl the plastic ends r eplacing
the shock cord aoo are attached to a. piece or 3/l6 ;Uco..rta \Ulich
1n turn may be secured to a moveab1e arm for basic support.

·. \ .
\
\
\

. ....
~\ ..
~·
.\ -~
"' · ;.,.·~,
~ . "\ ' -
. .\ \ J
•
·•. \
•.
. •.
\ :\
.
•
"·.. \
'. .. ,.,
'\ \\ 3/;6
v
•
__ .., />1!C~
c--v
0
D
..>
0

-:> ----./ ...._____

-.."'f'.-,.,
Fo i! ,.,., 'r.-..,4

-~ 10 e: v1G'V../

23
 APPENDIX H

Dear Bob - August 22 t 1959

Regarding Mr. Brooks Heathman, I believe that ha can be helped. As
we both know, we are dealing with the worst little killer ot all,
the most dreaded torm ot cancer - BY am BX w1th a rev other germ
thrown in. Bis cure v1ll req111re considerab1e attention. I wo11Jd
1uggest that he be placed on distilled water (onl.7 fluid) and good food.
Our perscr1ption is as tollovas (Gra~&: oran§e juiiit - use al.so)
. Treat v11h a d~uble actions first ~!ice ~ep~be 8 ~~es from the
heart v1th tbe .:na:x:1.mum 1ntens1ey directed to th• heart area. Determine
his c7cle blood tlov. It it is three minutes, then use 3 minutes time
on each frequenc71 it it is tive minutes then use 5 minutes time etc.
Do not move tube - suggest using an insulated (plastic or glass)
independent holder. First dq treat aa tollavsa
Streptococcus S minutes over heart
Sarcoma S minutes over heart (After using these t'requencies
Carcinoma. S mtnutes over heart then use the tvo tor T.B. at
Staphlococcia 10 minutes over heart tive minutes each).
next
TREAT cut ott toot area 1lovl.7 moving tube 8 to 10 inches awa7
from skin Up and do'1111 entire leg. Repeat the above provedure tor the
leg area. Use tlie same order as above listed. Tb1s v1ll take 'O minutes
ot time and possibl.7 a little more b7 the time 7ou adjust the frequencies.
I wotild tollw this v1th lov d1atharm.r ror 15' minutes 1n the cut oft
toot area slovl.7 moving the pada up and down the leg. Then t1ve minutes ·
with the pads on both sides ot th• stomach area to help the l.ymphatio
Sl"&t•~ along and 3 m1nutea over the top chest area for the same arstem
there. Have him lTing dovn wen the treatments are given (tlat). Tha.t
1.1, ~ down tlat cm a bed o• table or what have 70u.
Since his d1fticult7 is in the leg area, treat him daily and attar
one months t1me 1 70u v11l knov llhich va7he 1s going to go - 1n or
out or this vorJ.d. ·
And nov a vord about the 1nstr1ment. I trust 1ou have used 10000 volt
shielded vir• which 1s req111 red tor tbe tube connecticm - 1f not replace
vitb same am do not us• over 6 teet long wires and when using ~eep them
separated. Do not use aey metal 1n the tube area - use plastic tor the
holders as the metal v1ll set ~ t1eld up •Jld. absorb the energy tb~t"e
and ve w&nt the patient to absorb it. It is qtite possible now tbat
the tubes need replacement ard 7ou ma,- use th• better m1litar1 apeo
tubes aslan equivalent replacement. The coat is relatively the same
but the performance ia ·b etter. I had an al1nn1num mirror· put on . one . ·
side ot · m:f tube and tha7 did an excellent job. . .
Good luck w1 th BrooU, .

•
. -
. ..

24
 APPENDIX I

RDBERT P. !ITAl"l"DRD. M.
THDMAB CJ. DSWALC, M. C.
c. •
GEDRGE W. MARKUS, M. D.
'702 8ALt:M AVENUIE
DAYTON 6, CHIO

May 9, 1960
•

Mr. Earl Steiff

337 Cardi ff St.
•
San Diego 14, California
Dear Mr. Steiff:
Thank you for your letter of May 1st; I am sorry to hear
or the misfortune which has befallen your family.
•
At the present time, here in Dayton, we are using the
Rife Frequency Machine for investigational work only.
Because of some inconsistent results and lack of basic
fundamental clinical research here in Dayton, I have limited
the use of the machine, in the case of malignancies, to
•
carcinoma of the breast only. We have had some encouraging
results in breast cancer, but until we have a large enougi
group of cases of this type consistently n·cured", I feel
we dare not venture further in the field of malignancy. I
hope eventually to develop the knowledge to apply this
treatment successfully in other types of malignancies. •
Mr. Steiff, I am sorry that we are not prepared to
accept your Mother-in-law's case at this time. My
phone number, which you requested, is Cr.5-8116. Please
feel free to call me if I can be of any further assistance.
Sincerely yours,
•
..

Robert ?. ,Stafford,
RPS/mms
•

•
,
•

25 •
 APPENDIX J
p-; • -

•• .

'f .-.. •

!
;.
••
.. •

. . '
.. ,
.
.... . . .
... -. ..
•
,' ·. ~·-... '
.
- ~~1ved b71
"•
., .'

•' . . ... . .. ... ..

I • '
\ " :.
• • • ! ', • • • ·, • : • • : -~ • • • I • • • ' .:. • : • • ' ' :,. . . ~•

'. This instrument is loaned tor a period ot training tor a minimum ; · ~-· , .
· time ot two years and should be ret~d if requested thereafter. · - ~
. .. ·-
.,
,.
. ..
~
'
"' .
..•
.•
'.
-
'
. ,. . .
..

.I •
. . ·. .
•

.
...
. ~.. ....
...
·. •',, .. -:;·.
. .. '

... • .•
,,,... . -
,.. .
I

... :.
·~

.! ; '
.
.. .- .. .. . -.,•
'

. . •
~· "- . . .... •
. I ...
.. : ,... ·1
.. 1'
~·

' ....
. . , · -~it
-
•
. - ~
- '
.
• .i
4
..
.· • I

. .; '
. . ...
...._ .... - .. . . -· ~

..
....•"'lo: ~ •

• . .
26
.. I

•'
··- - ·- ---------- .. ·- -·--~~ --- -- ... . . ----~
•
.....-,.--....-----. _,,_, -·-..- -- - ----- - •

I • • . ."'
f . APPENDIX K •
CONTRACT
/ •
• •
REGULATIONS FOR TRAINING AND THE USE OF THE
RIFE FREQUENCY INSTRUMENT
•
:

,
•
. ,:
I. STATUS OF INSTRUMENT FOR FAMILY USE --
..
A. THE RIFE FREQUENCY INSTRUMENT (hereafter referred to aa INSTRUMENT)
•
i• loaned to a private individual using it, and it remains the ~ •
•
property of the RIFE VIRUS MICROSCOPE INSTITUTE (hereafter referred) .t
to• ae RVMI). - '
.-.
1. The INSTRUMENT will be loaned to the CONSIGNEE for a donation .'
of $17S.OO to be received by RVHI at the rate of $75.00 at the
time the contract ia validated, and $100.00 at the time of ••
. .

•
delivery of the INSTRUMENT; or, the full donation may be made
! •
at th~ time the contr.act . ia validated.
'·

2. Approxi~ately l(one) month muat be allowed for delivery of

herein-mentioned INSTRUMENT following date of validated
contract.
'

.•
•
3. An additional $2.00 per month donation (minimum) for the re-
placement of worn-out parts, tubea, and wear and tear in the
uae of the INSTRUMENT by the CONSIGNEE is to be donated in

4.
advance.

The $175.00 donation herein mentioned is alloted for the TRAIN-

•
lNG PROOR.AM which will give the CONSIGNEE a complete and full
course on the operation of the INSTRUMENT •
•
s. It ia the reaponsi·b ility of the CONSIGNEE to adequately insure
the INSTRUMENT for Fire, Theft, and Damage. •
6. Under no circumatancea will RVMI make any claims stating the
INSTRUMENT will cure any pathogenic disease. •

a. It ia designed to devitalize micro-living organisms- detri-

mental to mankind. The worthy body cells will overcome
the invaders and the body will heal itself with proper
food, rest, and aome needed medication. ·
'
• •
•

•
b. The CONSIGNEE ia to make no statements us·i ng the word
i "cure".
•
c. See separate document concerning the function of the
INSTRUMENT.
'
•
II. MEMBERSHIP IN RVMI

·•
•
A. The CONSIGNEE, OPERATORS, AND ALL TRAINEES, (see "C" p. 2) must be
membera of RVMI. The RVMI license requires that all persons re-
ceiving the benefit of the TRAINING PROGRAM and the use of the
INSTRUMENT must be members in good standing,

27 •
 •
----~--------------------------------~ -------..-.~-._... . . . ._,.._......,._. _ _ _ _ _ __
- ·, r '
. • -

. .. _..
_.
.;·
~ "' - ..,
_ _ _ _ _ _ __ _ _ _~~-~~~~--i-~

•
.
". CONTRACT
Page 2

• 1. There is a minimum donation of $2.00 for membership only.

.·•
2. For the privilege of x:eceiving literature, research in-
fonuation, etc., there is a minimum donation of $10 per year.
.•
..

• •
3. ''Application for membership" blanks properly filled out
must be sent by the CONSIGNEE to RVMI immediately following
the time application is made. ..
•

• ·.
a. These will include both types: •

-••
• 1.

·2.
Those with a donation for literature privileges •

Those with a donation for membership only.

• .' ...
.,,
'
. . . .
4. In order to become "Qualified ·a s an expert OPERATOR of FREQUENCY .
•

INSTRUMENTS" an APPLI~"T must be trained by an OPERATOR who has

• been certified by RVMI •

a. · Qualifying by ~aan-; of oral and written examinations is a

•

requirement. ·· ·
'
••
b. Fina ~·~i 11 be made by RVMI.
. . 1 accept nnce
•

• III. TRAINING PROGRAM

•

..
-.
.·
•

A. RVMI will furnish to the CONSIGUZE canplete instructions for the

TRAINING
•
PROGRAM a:-Ld tlie uDe of the INSTRUMENT •

• 1. It is mandatory fo~ the CONSIGNEE personally to know how to

operate the INSTRUMENT
. and to. thoroughly
.
understand its function.
• •

B. CONSIGNEE or a QUALIFIED OPERATOn may train a new OPERATOR.

•
• •
1. Such an OPERATO~ m3y not u~e the INSTRUMENT in the. possession
• •
of the CONSIGNEE fo• in~truc~ing TRAINEES or members of RVMI
until he has be~n appro"1ed by RVMI as a QUALIFIED OPERATOR •
•

C. TRAINEE • ..
1. A TRAINEE is a pe•son being taught in the use of th~ l~STRUMENT

• •
and its effectivity •
a. RVMI will make no claim or to.l erate a claim by the CON-
SIGNEE that any person is being "Treated 'or is receiving
•
"Treatments" under this program. It is the responsibility
of the CONSIGNSE to infonn each TRAINEE of this fact •
• b. No TRAINEE i c allo\1ed to .instruct another individual.
must first b~ccme a QUALIFIED. OPERATOR.
.
He

c. A TRAINEE ~ S phyoica l status is not to be diagnosed by an

OPERATOR. .
• 28
 .... ~
, -__,....- ----
,.... .
----~---
..,. . ~--·-....-.---------
. ..
·-------------- .
.... -·.·.• •...
..•
••
• • ,. •• t .;
/(
•
• .: . ..
'.
-. • •
... "
r
....• .. .
~

-. '.
- ......
;
\
•
, •• . ..
.. . . ,.· ... '
. ... .. ; \

. . ."
• • • • • • .. '
• ••
....... .
•
,.
~ • " "'··
•• . . .....
'II r .
. .... , -;.,
.• CONt•ttr . .. ..
..
:
• • • • •
. ....
IV• .ADVERTISINQ ...
.

..
. ~
. p. . . .3

..
..
'
."- .· ..
..•
.

•
. :
~
~
I
.. '
I
. ...
" ' ·r. ..,..".
. ...,
••

'
.
. .. .. ••
..•.
...··
.
.•
... .
..
.. • .
'
·i
ii. .~ "··
. ... .,,..
. ...

...1J'-
..•. . .-·..J
...
. . ..· ..
.. ~
'""'. . ..
• •
.

..
•
...,
'\

..
• t

... .. .,·,·..

.. ..
..
··-·
..
·-
. . ·. . ~. ""
.. . .. :. .. ....
. .
•
..

..
•
. ; ,·t.......
.. ...........
.;
'•..
~•
. ;~
,.
- ..,.
,..,
. . . ·-
.. .
•
•
.. ...
.

.; • \..- ' ..
.•
•
t • .;,I ·"' :
.. f
.: I • •

.,
..' .• . ·.~

•
' f. • ~
. .. :

•
:
." · '")..
·;
r
.

• •

.• .
• • • f

•
• • •

• -. • 1'
.. "
' •,
•••
·-.•... ••
. ......
I
.. •

-.
•

.
' • • ••
..• •"
•
'
•I
_}•
~ >
...·.:
. :. : ~.
• J •

....'
..
I •

' . ..
•
r
i

Signatur•,.· ' : .. ...

' ..
...
.
Con•1'n••. . .
.. • . . .. .
· ·S,Lni.odu•.
~·-:-
•

.. :..:·
,, .':'.:
' I • • ' ,... II

-,: ·.. ·rreaidellt • ..•""1

.
'
·•
.·
•
-..::::T"~4i . .
• • .. }-4 •• .• • . ' ·;.. :. ..'. . . '"~4' .. .
2 ·Y.· ,
•
..
..\
...
. • <II".·.
••

.
.
r .

.
..
r.;, . - •
...':. ~ . .
i ,.,
.. • •
-.· .
.
..
••
. ·.
~
. . . ..
_., . •

.:•>...
~,....~
. • ., .,
..
. . . ..:-..
• • .a. •• •
..

. .. .
: ' • ' •• I :
,~ "'),
~

-.
~ .. ' • t • I I 0 • ' •,, • ; ..
'
•• ..- . ••

.. . . . •..- ..,
.. •
1
..' ' -·
~
...... _'.
., • l..
"
.· . .. .. .
, ... .
•
t . . .. ·.... . ..

..
I• • .- •• •
. ..·,
. -~ • .• ,.
.4... ,
·~
-

;.:~~-=- _ _ _ _ _ _

.,
. J . :·•
, • •

. J
a

\ . .. us " .' .. """

,

. ,,.
_; -

; a

<"••
f T
4
. •
ttoi•I ·. ' t. . S~ture · . .~ ...~:~-.·~ : · ·:.:A"rerar.,., lWl . . .
. ... ,. .,...
. ·" .,
.
"'e
- • f • • • .. •

~ .. •
. ....
I

. ... ·-·
. • "' • , ..... • ""'- , , . • ·• • I •, • t ,., I

.:
#
... .. .• ., ' . . : .,,..,

'9;'
• •
~ • I • ¥ • . II>
.. .
/1,1 4 O
-'~.:;.:::aic~~;:;;:J::.....:~:....::L.r:...:::!:~~~!!:..--.-·
•
,, ' ' •
.~
' , •_ _. _· ._.
'. _' ·_ ·_ _...
:·. . .•.. .....
·:·_:·;,_
..: .•_.. .~ _·.~_~·,.:-.~l ·li....l ~.._.~'··"'I...· _·r_:-_.. ___· - • .
. ..
;.
. .. . . " .. .. . . .. '
.. '
,.... _;.,.
.. " f
·~·· Not!i'ry 'Pu.b--11~ Signtfwre· · .. · ·~.
~

l«it•lf ht;lic 1·11nature · ' ..

&fLd ! t a:rp 1

•
" •

~·
t't.~ .it.&1s.~ .
.-. .
.;_ . .. . .. ..t(P.
: : ...·
,.
· • • : ·....

~-
......
29
. . -
APPENDIX L

NEW DEVICE APPLICATION

California Pure Drugs Act
Division 21, Chapter 2, Section 262SS
CALIFORNIA HF.AI.TH AND SAFETY CODE

Name of applicant ___R_i_.f...,e_v....i...r...u...s.._.M..,.i....c...r...o..,.s...c....o_.p...eo;_;;I...n-s....t...i....t=-u=-t-e_ _ _ _ _ _ _ __

Address _______4~2~4~6;:;....;P_e~p~p~e~r=-D~r;iv~e~,....w.S~an..._~D•i•e~g~o~.~Caa•l•i•f··~·_.9.2•1~0~5--~
Date October 29 1965
Name of new device _ _F_r_e_g._u,_e..,.n...,c..,v..._.I,_n....,s....t,_r-.urn=e-..n-.t--.___________________

To the STATE B>ARD OF PUBLIC HEALTH

For the Director State Department of Public Health
2151 Berkeley Wq, Berkeley, California
Dear Sir:
The undersigned, JOHN F. CRANE I submits
this application with respect t.o a new device pursuant to Section 26288 of the
California Pure Drugs Act. Attached hereto, in duplicate, and constituting a part
of this application are the following:
(1) FULL REPORTS OF ALL INVF.STIGATIONS THAT HAVE BEEN MADE TO smw WHETHER OR Na!'
THE DEVICE IS SAFE FOR USE.
(a) An application may be incomplete or may be refused unless it includes full
reports of adequate tests by all methods reasonably applicable to show whether or net
the device is safe for use as suggested in the proposed labeling. The reports
ordinarily should include detailed data derived from appropriate animal or other
biological. experiments in which the methods used am the results obtained are clearly'
set forth. Reports of all clinical tests by experts, qualif'ied by ecientific
training and experience to evaluate the safety of devices, should be attached an:i
ordinarily should include detailed information pertaining to each imividual treated,
including age, sex, conditions treated, frequency of administration, duration of
administration of the device, results of clinical a.Di laboratory examinations made,
and a full statement of any adverse effects a!Xi therapeutic results observed.

(b) The complete list of components aDi or method of manu.t'acture ot the new
device used in each submitted report of investigation should be shown to the extent
necessary to establish its identity i! it differs from the description in parts (2)
or (3) of the application in any way that would bias an evaluation of the report.
(c) The unexplained omission of any reports of investigations made with the
device by the applicant or submitted to him by an investigator he supplied with the
device that would bias an evaluation of the safety of the device constitutes grounds
for the refUsal or suspension of an application.
(2) A FULL LIST OF THE ARTICLES USED AS COOONENTS OF THE DEVICE. Each component
should be identified by its common English name. If any proprietary preparation
is used as a component, the proprietary name should be followed by a complete
descriptive statement. Reasonable al.ternativ~s for any listed component may
be specified.

(3) A FUU. DESCRIPTION OF THE METIDDS USED IN THE MANUFACTURE, AND ASSEMBLY OF THE
DEVICE. Included in this description should be full information in sufficient

30
 ml DEVICE APPLICATION

Page 3

application concerning which no change is proposed. A supplemental application should

be submitted for any change beyond the variations provided for in the application,
that may alter the conditions of use, the labeling, the safety, identity, of the
device or the adequacy of mamfacturing methods, facilities, or controls. When
necessary for the safety of the device, a supplemental application may be required
to specify a period of time within which the proposed change will be made; an:i in
such case the distribution of the device after such change constitutes distribution
without an effective new-device application. A supplemental application is not re-
quired when the article is no longer a new device unless the proposed change itself
causes it to becane a new device. If a material change is made from the represen-
tations in an effective application for a new device before a supplement is effective
for such change, the application may be suspended. )
(8) IT IS UNDERSTOOD THAT ALL REPRESENTATIONS IN THIS APPLICATION RIDARDIID THE
COMPONENTS, CCMPOSITION, MANUFACTURING METHOOS, FACILITIES, CONTROLS, AND
LABELING APPLY TO THE DEVICE PRODUCED UNTIL AN EFF:&:l'IVE SUPPUMENT TO THE
APPLICATION PROVIDF.S FOR A CHAZm OR THE ARTICLE IS NO LOOOER A NEW DEVICE.
Very truly yours,
RIFE VIRUS MICROSCOPE INSTIDTUTE
(Applicant)

Per-1ohn F. Crane __,i;Ji..; <f/:~

OWner -~
(Indicate authority)

This apP+icati.on must be signed by the applicant or by an authorized attorney,

agent, or official.
The data spe~ified umer the several numbered. heading should be on separate
sheets or sets of sheets, suitably identified. The sample of the device, if sent
under separate cover, should be addressed to the STATE BOARD OF PUBLIC HEALTH,
Bureau of Food arxi Drug Inspections, arxi identified on the outside of the shipping
package with the name of the applicant an:i the name of the device as shown on the
application.
The applicant will be notified of the date on which his application is filed.
An incanplete application, or one which has not been submitted in duplicate, will
usually be retained but not filed as an application provided for in Section 26288
of the Pure Drugs Act. The applicant 'Will be notified in what respect his appli-
cation is incomplete. ·
ALL APPLICATIONS AND COR.trESPONDENCE SHOULD
BE SUIMrTTED IN DUPLICATE

( 2-20-57) Fo:z:m F&D-l730

31
 APPENDIX M
p__-F ~
M.~ C kOSCO:?.'E I
~====-=-=- .. -- · --= ·· ==-=-=.-..::-
....=-=-
..
=
. _____ ____ _ _ __ .. _ _ - - - -· - ·- -

..,, __ .. , N
' .., --=' -. P-:: ~· pe .r ..
'!"'\,_ .· ", '° D.'..::- ;z c ,
"'t .
s
P r ..::- :-, e : 2. 8!- 0278. T
- T R
October 29, 196 5 FREQUENCY
f1
·-·'' State ~;oarr-:. of Public Health E
.. .r 2151 Berkeley Way N
- R ~P- r~·: elsy, Calif. T
- t.1 s
r.~ntle"."".en:

'::''.-ie ~7~\·7 D:CVIC::: APPLICATION is subni tted wi t;1 the

followinq reports:

1) l'.~r-ench: }., - PESt:LTS '1:1ITE FPEQUENCY n:ST'R.l:JJl~i;'l'C J'l.F'IER

~-~ ~~. DIAGNOSI$ AUD ~~EDICINES FAILED TO HELP ?EOPLE.

2) 1 C cc:-';)ies cf labelinq of Frequency Instrur:\~nts

~) I~·7 ST'RUCT!0NS :'OP. THE US!~ OF' THE RIFE FRI:•)UE:>iCT

!?7ST~D··~7\7' - CO';">yric;htcd 1960

4) . I:lST~t:CTIOH ~-Wml\L FOR i·10DI:L 377 Sine and Square Wave

Generi'lto.r of F'r~quency Instrument •.

5) I:JTRODUCTION TO ELECTRON THERAPY by John F. Crane

'5) ZLECTRON T!iEP.APY - Report l~o. 1456 by J'ohr. F. Crane 1959.

7) HISTORY OF TH£ DEVELOPMENT OF A SUCCE!iSFUL TP..EATM.S~4T

.!:OR CAt·: CSR Alm OTHER VIRUS, =:.AC'l:'l:.RIA, lu.'>;D FUi.;·c r.
Copyrighted by John F. Crane 1S54.

8) ELECTRON THEP.APY PRO?OSAL FOR RES:C:P.RCr~ G?.ANT by

John F. Crane April 1965.

't'he foreqoir.g constitutes the inforr.1ation and tbe wcrk

carried forward after 1958 on transduc~r type Frequency
In~trurnent which has proven safe to use withcut any side
effects on the human anatomy with the electrocution of
harr.=u1 miero-organisrns without hartn to i1uman colls
coupled with a new effect to assisting the meta.Dalis~ now
•:Ti t !1 an uplift and of eliminating pain and shock fror:1
?aralyzcd nerves and body cells.

Submitte<l in duplicata 1

(,1
.---/.·., ...
~
Jc~n
....
F. Crane , rresident P-VMI

32
 APPENDIX N
STAT! OF CALIFORNIA-HEALTH AND WELFARE AGENCY EDMUND G. BROWN, Go..,.rnor

DEPARTMENT OF PUBLIC HEALTH

1151 BERKELEY WAY
IEIJWEY 9470.C

,V

November 17, 1965

Mr. John F. Crane

Rife Virus Microscope Institute
4246 Pepper Drive
San Diego 5, California
Dear Mr. Crane:
Subject: New Device Application -
Frequency Instrument
An initial review has been ma.de of your application dated October 29,
1965 and received by this office on November 4, 1965 .
Your application fails to indicate which enclosures are specimens of
the labeling and advertisements for such device as set forth under Section
26288 (f) of the Health and Safety Code. Upon receipt of this information,
a determination would follow as to whether other requirements of the
code section have been met.

Section 26288 (a) of the Code reads as follows:

"Full reports of investigations which have been ma.de to show
whether or not such drug or device is safe for use, and
whether such drug or device is effective in use;"
In this regard, you are advised that the application and supportive
material submitted does not satisfy the above requirement. It is re-
quired that :f'u.11. reports of adequate tests by all methods reasonably
applicable, including clinical tests by experts qualified by scientific
training and experience to evaluate the safety and efficacy of this
device accompany this application. Until all the requirements of the
code section are met, this application mu.st be considered incomplete.
Very truly yours,

~~ec:?-- //f.J & d

.~~es W. Bell, Chief -
Bureau of Food and Drug Inspections

JWB
gsl:ev

33
 APPENDI X 0

fl>MUNO G. aaOWH, a..-

DEPARTMENT OF PUBLIC HEALTH
2U l HRIClLEY WAY
IERK!l.EY 9.0CI'

February 10, 1966

Mr. John F. Craoe, President

Rife Virus Microscope Institute
4246 Pepper Drive
San Diego1 California 921.05

Dear Mr. Crane :

Subject: New Device Application -
Frequency Instl"ment
This is to acknowl.edee receipt of the statements of Dr. Leslie Drown,
D.C. and Dr . Charles w. Bulmer, D.C. in regard to the safety of the
Rife Frequency Instrument.
We again wish to refer you to Section 26288 (a) of the Health and
Safety Code which reada a.s follows:

"Full reports ot investigati ons which have been made to

show whether or not such drug or device is sate for use,
and whether such drug or device is effective in use; "

L et me emphasize that this section requires full reports of investi-

gations to determine safety and. efficacy. In this regard, the two
statements do not satisfy the above requirement.
Very tl"\Lcy yours ,

ames W. Bell, Chief

Burea.u of FOOd. and Drug Inspections

JWB:ev
cc: Los Angeles

34
 APPENDIX P

R.• FE M ~'C P...n.3cO.r ~ I

..
'""="'=""~===-·= ...~..=-··====-·=·=""'·=- ·=· =--:==·----- - . .
-=...= N
P e:rpe:- LJ !" ~ve, S c. r-~ D .'. ~ g :; : C2. ~ ~fc· r!'l:.a
s
; : ~ c :, z : p (: ·~ d f.' T
- I ..
R
'!: BBFl'..P'f
FREQUENCY
..,. 1" ···r+++ Dr. Lester Breslow,f.l.D. M
Director of Public Health E
i.' 2151 Berkeley Way N
Berkeley, Calif. 94704 March 7, 1966 T
- '.. ·~ s
- N Dear Sir:
We have sent in an application for a new device and
have complied with all the requirements. We have
received nothing but dereliction of duty from James
W.Bell, Chief of Food and Drug Inspections .
Clinical evidence was included along with reports
of absolute safety which can no longer be denied.
Your department~ practice of class discrimination
to foreclose free enterprise and to stop the use
of Frequency Instruments is a national disgrace as
well as a monopolistic -practice in depriving the
people of this country of their right to live.
If the deprivation of our civil rights continues,
there seems to be grounds for Federal grand jury
action. We. ask that this application be processed
and approved without further harrassment and delay.
Let me assure you that the previous phony hearing
held here in San Diego does not carry the present
consequences.

Sincerely yours,

RIFE VIRUS MICROSCOPE INSTITUTE

cc: Governor Edmund G. Brown
: RVMI Members and Friends
The International Association of Cancer Victims
And Friends
: Dr. Char~es W. Bunner, o.c.

35
 L)
.I:'
. T: .
•• r
.,.....
£... "\-} R. t~ S
APPENDIX Q
. C•
'1'\ l~ . F 0- :::: (·. 0 -··
1
..J -
";:"'
j;-'.._ I K S -: : T l 1 'I E I
•
·-
·=--:";".--=·-=·====

,..-·cc.
-; t. .. ! ;
----::::".::--=-=-=-:: '!":
_

D -r .:... -"• e .
.--:::•• =:-::::--:-:-.-=-:'.:""':'.
. · -=-~-::-::

-
S -;: ,.,
.. ..
.. -==:-.·:-:.-==--=-==-==--::":.-~--==-=-==
n ; ... gr
.&,..- .:. ......, \.I :

r j }-_ (. ~ e : 2 8 1 - 0 2 7 6
--:-=-==-=-=-==-=

C. a..:.- 1_
. f cr:; ... a

T
N
s
- .t.

'T•
.,.
L
q '!:' ~ i · D '-··
•• •- -..1.0.\..r: l: .l
R
FREQ u El\iCY
.· 1.
•
- ..- ~ E
- T United States District Court May 6, 1966 N
- R District of Utah T
- s
-
,_.,
!.'i
Salt Lake City, Utah
Deputy Clerk: Re: C 37-61
•
United States of America
vs
One Article Device***"Rife Frequency
lnstrument" ••• etc.
•
Per yourletter of July 17, 1961 [Wayne Christoffersen by
Hana Shirata] you state that an order was made for the release
of Exhibit.
Please advise us of the disposition of this $1000.00 Frequency
Instrument - does the Court still hold it and if it is released •
could it be sent to its lawful owner - John -F, Crane/?
We understand that this instrument was unlawfully seized from
Dr. George E. Eason, N.D.
•
John F. Crane, President
RIFE VIRUS MICROSCOPE INSTITUTE
•
The item in question was released to
W. H. Lightfoot, Resident Inspector,
Food and Drug Admin:iS:ration on June 9, 1961
as per order of the Court. For further information,
filed iri United States District
Court, District of Utah •
please contact the United States Attorneys Office.
MA'f 9 1965
ANDREW JOHN BRENNAN, Clerk
-
By: c. ....•
~
'
I
I
·• ;"w ~ /
,,/ . :.,,.- ·,..·-..-·
. ,:.,.v"""-./_.: .-,
j
•
· DE111ty Clerk

36
• ·' ~
APPENDIX R
~ 1R-r-5
i.J c-.I·~ ·- r . · ;-
M -; r # F·. . ~.
- : :K 5 T l ':'" Li 7 E
_ 1 .... . I
-=
- -~--
~-~-~
· -~
-- =-=-=-~·-
~-~-~
- -==~-=.====-=---
- --~- .. - - ..
·---.~~~-=~~~~~~~~- ---- ·---- -! --·-
·~

,. . .
.~ ') _l
Perpe1 Dri ve , ....,. - r
;;..
., -- .
.._, r,:_ _ _ r 2 -
. . -
• ,... ,... :_ , N
s
• } • #
~ ' -
'
• -
.,. •
- ~I .J , ·-· - -' .. • ~· - .: - G.

1' - .-. :. e '. 28 1- 027& T

• •
-
r.~
J Ji -

+++++++
-
l
· T ' n ;\ ~·
t"'..r-.t"
·J
.l

U.S.District Court May 12,1966

R
FREQ UEl~CY
f1
- ( District of Utah E
- 'T' Salt Lake City, Utah N
-· R T

• -
-· N
(1
Deputy Clerk: Re: C 37-61
s

You have given us two names (ll W.H.L~ghtfoot, Resident

• r·nspector, Food and Drug Administration and that of the

U.S.Attorneys mffice. Would you please send addresses
for the two above referenced sources so that we may

• contact them. Thank you •

• .........:::::;_--~John F. Crane, President

RIFE VIRUS MICROSCOPE INSTITUTE

• U.S. Attorney's Office .

Room 200 U. S. Courthouse Bldg.
Salt Lake City, Utah

·• WILLIAM T. THURM.AN
UNITED STATES i\ITO~~EY
200 U. S. POST OFFICE & COURT
HOUSE BLDG. Filed in Un!ted States District
SALT LAKE CITY, UTAH 84101 Cowrt, District of Utah
We are unable to find the address of W. H. Lightfoot, one-time

• Resident Inspector for the Food and Drug Adm. You might
obtain the information you desire from the Food and Drug Adm.
Dept. of Health, Education, and Welfare, Rm. 573, New ~
~ ': .'-.\' ~ · \\.': ~
\ · · - ·-- ·· "
/7 ; :. . . ~/
Customhouse Bldg., Denver, Colorado 80202 ~tt~~t;::·~~fz(,rt."~1~.:. t.f
I'- .__., Clerk

• 37
 APPENDIX S

Al\IERTC . \~ '.\11 ·'. l>l< '. \I . : \SS()( 'L\ ' l'I() ,

535 NORTH DEARBORN STREET• CHICAGO, ILLINOIS 60610 • PHONE (312) 527-1500 •TWX 910· 221·0300

LAW DIYISIDN

BERNARD O. HIRSH,
Ouector

DEPHMICT Of
lllYtsTIUTION September 14, 1967
H. OOYL TAYLOR,
Ouector

Miss Ellen L. Adams

2779 A Street
San Diego, California 92102

Dear Miss Adams:

This is in reply to your letter of September 6,

asking for information on the "Rife Frequency Instrument. "

We attach photocopies of pages from a report of

the Food and Drug Administration, issued in 1962 . This
concerned the seizure of a Rife Frequency Instrument i~ an
action filed in federal court, because it was misrepresented
within the meaning of the federal law.

You will notice reference in the Notice of Judgment

to John E. Marsh. The file contains an indication that Mr.
Marsh was a defendant in the case brought by the State of
California against several individuals , who were convicted
by a jury for attempted grand theft and conspiracy to commit
grand theft, and for conspiracy to violate the Business and
Professions Code of California, prohibiting the practice of
medicine without a license . The conviction was reversed on
the first two counts , but affirmed on the third by the Supreme
Court of California. Involved was the sale of Rife Frequency
Instruments to residents of California, at prices ranging from
$175 to $2,000 , under the guise of "donations ."

38
 APPENDIX S (2nd page)

92 FOOD, DRUG, AND COSMETIC ACT •

[D. D.N .J .
6616. RIFE FREQUENCY INSTRUMENT. (F.D.C. No. 45509. S #17-356 R.)
QUANTITY: 1 device consisting of a variable frequency generator
with a controlled power output designated "RIFE FREQUENCY
INSTRUMENT'' and a frequency counter designated ''Model WE-110
Counter R.V.M.I. San Diego, Calif.,'' at Salt Lake City, Utah .
~[Seized without Search and Seizure Warrant ... ] Taken from the
office of Dr. George Eason.
SH IPPED: 8- 1-60, from Sa n Diego, Calif., by RIFE VIRUS MICROSCOPE
INSTITUTE.
ACCOMPANYING LABELING: Four page leaflet entitled "C on tract"; two
letters signed by John E. Marsh, one dated 9-12-60, and one on
the Rife Virus Microscope Institute letterhead dated 7-17-60;
and an In s truction Manual
RESULTS OF INVESTIGATION: The device was a variable frequency
generator with a controlled power output used in conjunction
with a Model WE-110 frequency counter. The device included two
metal electrodes with insulated handles which were intended to
be applied in direct contact with the patient's body.
LIBELED: 3-13-61, Dist. Utah. [Coerced confession by the U. S.
District Court in violation of the Fifth Amendment and the
Sixth Amend ment.]~
CHARGE: 502(a) - when shipped, the accompanying labeling of the
article contained false and misleading representations that the
article was adequate and effective as a treatment for devital-
izing micro-living organizms detrimental to mankind, and thereby
overcoming such conditions as cancer, colds, tumors, leukemia,
athlete's foot, varicose veins, tetanus, typhoid, gonorrhea,
staphylococcus, pneum onia, streptothrix, TB virus, carcinoma,
sarcoma, treponema, abscess, fistula, hemorrhoids, hernia,
irritations, arthritis, bursitis, palsy, diseased lymph node s ,
acne, cystitis, b.oils, bubonic. pi ague, diptheria, eleph ant iti s ,
fungus, impertigo, hardening of the artieries, leprosy, mo l es ,
multiple sclerosis, poison o~k, poison ivy, poliomyelit.is, skin
eruptions, spinal meningitis, warts, constipation, typhoid
fever~ colitis, catar·ac:t, glaucoma, leakage of the ··h·ear.t,
cor onary thrombosis, tetanus, peptic ulcers , and other abnormal
and dosease conditions.
6581-6620 NOTICES OF JUDGMENT 93
DISPOSITI ON: 5-29-61~ De'fault-~elivered to the Food and Drug
Administration.
~The above charge was false in that no c laim s were made at ,all.
This was stipul ated in the contract carefu lly ignored by the
United States Governme nt s ued herein for common grand theft
with out l eg al ca use1 by John E. Ma r sh and John F. Crane. ·
THE IN STRUMEN TS WERE NOT SOLD AS FALSELY ALLEGED.
39
 APPENDIX U

Patented Sept. 10, 1929. 1,727,618

ROY R. RIFE, OF SAN DIEGO; · CALIFORNIA.

MICROSCOPE LAMP.
Application filed August 2, 1927. · ~erial No. 210,099.

My invention relates to microscope lamps is, a< sectional elevational view thereof
and the objects of my invention are: first, to through .~4 qf Fig. 3 ~vith the light bulb
provide a lamp of this class which is posi- therein show1i by dotted lines. ·
tiond directly below the stage of the micro- , Similar characters , of reference refer to
5:scope; second, to provide a device o:f this similar parts and portions throughout the 5.5.
class which fits into the mirror yoke of the stweralviews of the drawings; ·
microscope ; third, to provide a device of The 1lamp housing 1, famp socket supp9rt
this class in which the intensity of light may 2, lamp socket ·3, incandescent · lamp 4, ·re-
be easily controlled; fourth, to provide a de- flector 5, lens support 6, lens 7, cord 8, .and
10 ' vice of this class in which the lamp is of the rheostat 9, constitute the principal parts 60
ample intensity for the most minute or mi- and portions of my . microscope ·lamp; · ·
croscopic studies; fifth, to provide a device of My la111p is positioned below the stage S
this class which is attached to the microscope and at the side thereof opposite the objective
and is not an accessory thereto; sixth, to pro- 0, and is mounted in.its preferred form, on
15 ' vide a device of this class which provides the conventional mirror yoke B of the ,mi- 65
superior quality of fiat and uniform light croscope, in place of the usual mirror as will
which is excellent for microscopic and micro- be described later. ·
photographic work; seventh, to provide a de- The hcmsing 1, i::: cylindricfl,l, is open at its
vice of this class which is well ventilated to ends and is provided with a plurality of p~r~
20' prevent excessive heat; eighth, to provide a £orations 1" in the walls thereof. Extend-. 70
device of this class in which the light emitted ing. from an opening in the side wall. of the ·
therefrom does not fluctuate and therefore housing 1, is a lamp socket support 2. Its
reduces to a minimum the strain on the op- inner .end is flanged and is soldered or other-
erator's eyes; and ninth, to provide a device wise secured to the housing 1. The support
25 . of this class which is simple of construction~ 2, is provided with a clip me~ns 2" for fric- 75.
easy to install on any conventional micro- tionally engagirig the la1np;socket 3 which) s
scope, neat in appearance, durable, efficient positioned therein. The lamp socket 3, is
in its action, and which will not readily de- similar. to the conventi.onal automobile lamp
teriorate or get out o:f order. socket and may be ad]lista~ly positioned in
30 With these and other objects in view as the lamp socket support 2.. An incandesc~nt so
will appear hereinafter, my invention con- lamp 4 is removably secured .in the lamp
sists of certain novel features of construction, socket. 3.....Positioned over the low(lr open encl
combination and arrangement of parts [1.nd o.:f the hqusing 4, ·is a ·reflector 5, which is
portions as will be hereinafier described in preferably . metallic . and which is provided
35 - detail and particularly set forth in the ap-
with a reflecting surface on . its upper side. 85
pended claims, reference being had to the ac- An opening 5" is provided in the reflector .5,
companying drawings and to the characters which is 'centered<therein and which, with
of reference thereon which form a part of
this application, in which: the perforations 1a in :the housing 1 , permits
. 40 · Figure 1 is a side elevational view of my tl,iorough circulation of .air ·around ·the lamp 00
microscope lamp shown in . connection with 4. The :hole 5", also pe'r mits the light emit-
a conventional microscope; Fig. 2 is a top or ting portion of ·the lanip 4 to .he more easily
plan vie>v of my microscope lamp shown in centered on the axial line of the microscope
connection with a rhe.ostat means for vary- la.ihp~ '. Positioneclover the ~lpper open end
45 · ing the intensity of the light of the lamp; of the housing .1, iS ·a lens support .6, which ·. !)5 ··
Fig. 3 is an enlarged sectional view of my is provided with a large central opening .6a,
microscope lamp through 3-3 of Fig. 4, therein, The lower. 'edge of the opening 6", .
with certain parts shown in plan to facilitate has . an inwardly extending flange 6b, .on
the illustration, and with the light bulb which res.ts the lens 7. ) The lens 7 is plano~
50 . therein shown by dotted lines, and Fig. 4 COil;V~X ~pdjs . frosted on its plany ~nd ' ·,.
inner
.- ...
· ---
.. i-oo ··
,

41
 2 1,727,618

side. The lens 7, is held in position by means port and shiftable therewith opposite the
of plastic material 7a. objective.
The cord 8, which! furnishes electricity to 4. In a means of the class described, the
the incandescent lamp 4, is connected with combination with a microscope having a
5 the rheostat 9, which varies the strength of stage, an objective mounted at one side 70
current and thereby regulates the intensity thereof, and a conventional mirror support
of the light of the lamp 4. As shown in at the opposite side of sa.id stage, of a lamp,
Fig. 1 of the· drawings the microscope lamp mounted on said support and directed to-
is mounted ·under the stage of the micro- ward said stage.
10 scope in place of the microscope mirror. In testimony whereof, I have hereunto set 75
For this purpose, the housing 1, is provided my hand at San Diego, California, this 16th
with two oppositely disposed openings in day of July, 1927.
the side walls thereof in which ·extend pro- ROY R. RIFE.
jections of the mirror yoke B.
15 It is obvious ..from the construction as 80
illustrated in the drawings and included.in
the foregoing specificatiori, that there is pro"
videcl a microscope lamp as. aimed at and
set forth in the objects of my invention, and
20 although I have shown and described a par- 85
ticufar construction, combination and ar-
rangement of parts and portions, I clo not
wish to be limited to this particular con-
struction, combination and arrangement, but
25 desire to include in the scope of my inven- 90
tion the construction, combination and ar-
rangement substantially as set forth in the
appendecl claims.
Having thus described my invention, what
30 I claim as new and desire to secure by Let- 95
ters Patent is:
1. In a microscope lamp of the class de-
scri?ed, the c?mbination with a microscope
~av~ng a stat10nary base and a pivotal ob-
35 Jective, .of a cylindrical housing· pivotally 100
~oun_ted betwee_n saic1 base and said objec-
tiye m. conn~cti~m with and in alignment
with said ?l;Jective and movable therewith,
a lens posit10ned over the one end of said
40 housing, a reflector positioned over the other 105
encl of said housing, and an incandescent
l~mp extending into said housing .from the
side thereof at a right angle to its axis be-
tween said lens and said reflector.
45 ~· In .a microscope lamp of the class de- llO
scriJ:ied, the c?mbination with• a microscope
~av~ng a stat10n~ry l;ase and .a pivotal ob-
Jective, of a cylmcl~'ical housrng pivotally
~?un_ted betwec.:n sa1c~ base an~ said objec-
50 ti~~ m. conn~cti~:m with and m alignment 115
witn said obJective and movable therewith
a le~s positioned over the one encl of saitl
housmg, a reflector positioned over the other
.end of. saic~ housi~g, an ~ncanclescent lamp
55 extenclrng rnto said housmg from the side 120.
t~ereof ~t a right angle to its normally ver-
t~ca~ axis, and ~neans t_o ~acilitate the posi-
t10nmg of the light emittmg portion of said
60
lamp on the axial line of said housing. 125
3. In a means of the class described, the
combi.nation with a· microscope having a
stage and an objective at one side thereof,
o:f a support carried by and shiftable with·
65 said stage, and a lamp mounted on said sup- 130

42
 APPENDIX V

:sept. 10, 1929. R.R. RIFE 1,727,618

MICROSCOPE LAMP
Filed Aug. 2, 1927

43
AP PENDIX W

e
~ OPAQUE ILLUMINAT I ON

10 13
-9 ·12
8 II
6---1 ~'?---- 7
~~~:_-5 IRIS DIAPHRAG.M

3 ......--4 COLOR FOCUSER

-.

••
I
I ,___z INVENTORS:
.

ROYAL R.RIFE
JOHN. . F. CRANE. -·

PRISMATIC
. . VIRUS
. .. MICROSCOPE
patent Pendi'ng
Fig. 2
4 4·
APPENDIX X
ASSIG(\r~1 r·;~·j' 0~·· IN v l~l\ T'lC)N OF
UNIVERSAL MICROSCOPE, OPTICAL AND ELECTRONIC SYSTEMS
WliE?..EAS .. I. ROY.'\..L F... RIF·E, a re::ide:it cf S'1ri D1~g:.> Cl')1..!r.:':r ,
California, have i::ver..tcd a ccrt~i:"l nc\•: ar.d use!-.il r~ic=-~~~ ...,~~' io1· \i,.·hich
I am about ~o make .:ipplic~tio'' fl\r 'i•.:?tters .i;atct:t of th<! u:litcc! State~; Cl-'1C

\\'11.EREl... S, JOH~ F. CI'J~NE, n resident of San Diego County,

Caliiorni&l: is desirous of -acquiring an interest in said inv~!'ltior. Q:ld in
t"le letters -patent to be ob!ai ned the r:-efor;

NOW, THEREFORE. IN CONSIDER..'\.TION of the sum of Five

Hundred Dollars ($500. 00), receipt of \vhicr.. is ac~:.:io\vledged, Royal ·R.
Rife hc1·cby sells. assigns and transie::-s to John F. Cr~.n e the f~ll a.nd
exclusive ?"ight to the said ·invention, includi:".g all '\Vorkir:.g modP.lS or
said inve!'"i.ti~n \•1hich have not pre"riously been sold, possession of wh\ch
is ackno\,,.ledgcd to b~ \\ ith J'·:>hn F. Cri."le. I further assign :ny right to
1

the applicatior: f~~ a patent and in and to any and all cori.ti:-luations. divi-
sions and ren~".vals fr,.ereof, and in and to an)~ and all United States Letters
Patent granted ~hereon and in and tC\ an)' and all reissues and extensions
thereof as v;~ell as all Letters Patent :Jnd dpplicatjons therefor in any
foreign country, and I do hereoy :iuthorize and requP.st tr~e Ccm:nissioner
o! Patents to issue the said le!ters patent to the said John F. Cra"e as
. the assi;~nce of my entire right .. ~it1e and interest in and to the sam~ for
the sole use and behoo! of the Seiid Jolin F. Crane and his legal repre-
S ,.._ .. _ ...... c:
•
--~ . . . . . . . . . . I' __..,,,.

. .
I . further ag~ee that on requ~st o! the assi:ant!e and a.t its expe~se,
but without further consideration, I will testii}' iil any p~oceedir.g a.:-Jll •
exec...ite all proper papers and othen"'·ise act to aid assign\?e in obtaining
and eniorcing p:-oper patent title and protection in said assignee.

. m
TESTIMONY VIHEREOF~ I have hereunto set my hand a.."'ld
affbCed m)· seal on this 4- -lk. day of ~!arch, 1968.

0Y_4L R. RIFE •

.3676 Zola Street

WlTNESS: • Point Loma, CA
Richard D. Streeper

Attorney at. Law

STREEPFR AND SHANNER
2067 lst Ave·•. , San Diego, CA.

WITNESS:
John F. Crane
.: ?bhn. F: ~ret~
President, Rife Virus Microscope Institute
4246 Pepper Drive, San Dieqo~ CA~ 92105
45
APPEND IX "l

RIFE FREQUENCY INSTRUMENT

DI AL NUMBERS

and GROUND

"R" -

.__ Anode and Cathode

AUDIO SQUARE WAVE GENERATOR

..
....... --·
...
~F • ..... •

- ..
·-
·
• • •
.. ..
•• ...• ••
• •
C•.)
tit F

-- -·.··..,..." -··-·
· . ...
.

...
ftza
... II

Sguore Wove Range : 60 - 30,000 c. p.s.

46 Roted Output Power: 100 milliwotts into roted load (10 volts ocrou a 1000
ohm resistive lood).

DIAGRAJ\tl OF INSTRUIVIENT

FOR ELECTRON THERAPY Patent Pending

 APPENDIX Z
United States Patent r191 [11] Patent Number: 4,622,952
Gordon [45] Date of Patent: Nov. 18, 1986

[54] CANCER TREATMENT METHOD 4,325,361 4/1982 Harrison .............................. 128/1.3

[76] Inventor: Robert T. Gordon, 4936 W. Estes, FOREIGN PATENT DOCUMENTS
Skokie, Cook County, Ill. 60077 522688 5/1977 U.S.S.R ................................ 128/1.3
[21] Appl. No.: 681,697 789119 12/1980 U.S.S.R ................................ 128/1.3

[22] Filed: Dec. 14, 1984 Primary Examiner-William E. Kamm

Attorney, Agent, or Firm-Laios, Keegan & Kaye
Related U.S. Application Data
[57] ABSTRACT
[63] Continuation of Ser. No. 457,715, Jan. 13, 1983, aban-
doned, which is a continuation of Ser. No. 96,413, A process for the treatment of cancer by the application
Nov. 21, 1979, abandoned. of external electromagnetic energy capable of achieving
biophysical alterations in the intracellular structure of
[51] Int. CJ,4 ............................................... A61N 1/42 cancer cells in living tissue, including stimulation of
[52] U.S. CI ...................................... 128/1.3; 128/422;
intracellular production of interferon. The process ac-
604/20
[58] Field of Search .................. 128/l R, 1.1, 1.3, 1.5, complishes these biophysical alterations by tuning an
128/422, 736, 804; 604/20, 21; 424/l.l, 9, 85, external electromagnetic energy to the resonant energy
147; 514/824, 889 absorption frequencies of the intracellular structure of
the selected cells and then exposing the subject to this
[56] References Cited tuned electromagnetic energy field. Alternatively, the
U.S. PATENT DOCUMENTS field can be tuned to the frequency which has been
calculated to be closest to the resonant frequency of the
3,474,777 10/1969 Figge et al. ........................... 604/28
3,489,522 1/1970 McConnell ............................. 424/9 cancer cells and furthest from the resonant frequency of
3,542,915 11/1970 Bodkin ................................ 424/147 the normal cells. The process may be further enhanced
4,005,699 2/1977 Bucalo ................................. 128/1.3 by the intracellular absorption of selected materials
4,027,021 5/1977 Underwood ........................ 514/889 designed to alter the magnetic susceptibility and there-
4,186,729 2/1980 Harrison .............................. 128/1.3 fore the resonant energy absorption frequency of the
4,202,323 5/1980 Zweig et al. ......................... 128/1.1 intracellular structure.
4,269,826 5/1981 Zimmermann et al. ............. 128/1.1
4,303,636 12/1981 Gordon ................................ 128/1.1
4,323,056 4/1982 Borrelli et al. ....................... 128/1.3 17 Claims, 1 Drawing Figure

injection of metabolic and activity varying

substances into living tissue having cancer
cells and normal cells
I
t
(magnetic particles)

t t
(oxidation source) (intracellular heat generation)
t
transmitting electromagnetic energy to tissue
over range of frequencies

Determining resonant absorption frequency o!

the cells

exposing the cells to external alternating

electromagnetic tunes to resonant frequency
of cancer cells to produce biophysical changes
in the cells

47a
U.S. Patent Nov. 18,1986 4,622,952

injection of metabolic and activity varying

substances into living tissue having cancer
cells and normal cells
I
t
(magnetic particles)

t t
(oxidation source) (intracellular heat generation)
f
transmitting electromagnetic energy to tissue
over range of frequencies

Determining resonant absorption frequency of

the cells

exposing the cells to external alternating

electromagnetic tunes to resonant frequency
of cancer cells to produce biophysical changes
in the cells

Ji_j- I

47b
 4,622,952
1 2
that cancer cells die at lower temperatures than do
CANCER TREATMENT METHOD normal cells. The temperature at which a normal cell
will be killed and thereby irreversibly will be unable to
This is a continuation of co-pending application Ser. perform normal cell functions is a temperature of 46.5°
No. 457,715, filed on Jan. 13, 1983, now abandoned, 5 Centigrade, on the average. The cancer cell, in contrast,
which is a continuation of application Ser. No. 096,413, will be killed at the lower temperature of 45.5° Centi-
filed on Nov. 21, 1979, now abandoned. grade. The temperature elevation increment necessary
INTRODUCTION to cause death in the cancer cell is determined to be at
least approximately 8.0° Centigrade, while the normal
This invention relates generally to a process for the 10 cell can withstand a temperature increase of at least 9.5°
treatment of cancer in living tissues and is an extension Centigrade.
of the technology described in U.S. Pat. No. 4, 106,488 It is known, therefore, that with a given precisely
issued Aug. 15, 1978; and U.S. Pat. No. 4,136,683 issued controlled increment of heat, the cancer cells can be
Jan. 30, 1979. More particularly, the present invention selectively destroyed without injury to the normal cells.
relates to method for achieving biophysical alterations 15 On the basis of this known differential in temperature
in the intracellular structure of cells. These biophysical characteristics, a number of extracellular attempts have
alterations include thermal changes, stimulation of the been made to treat cancer by heating the cancer cells in
intracellular production of interferon, stimulation of the the body. This concept of treatment is referred to as
intracellular production of prostaglandins, and the hyperthermia. To achieve these higher temperatures in
treatment of cancer by intracellularly killing the cancer 20 the cancer cells, researchers have attempted a number
cells without injuring the normal cells.
of methods including inducing high fevers, utilizing hot
BACKGROUND OF THE INVENTION baths, diathermy, applying hot wax, and even the im-
plantation of various heating devices in the area of the
There are presently a number of methods and tech-
cancer.
niques for the treatment of cancer, among which may 25
Presently, none of the various known approaches to
be included: radiation therapy, chemotherapy, immuno-
treat cancer have been truly effective and all have the
therapy, and surgery. The common characteristic for all
of these techniques as well as any other presently common characteristic of approaching the problem by
known technique is that they are extracellular in scope; treating the cancer cell extracellularly; the only known
that is, the cancer cell is attacked and attempted to be 30 exception being, U.S. Pat. No. 4,106,488, Cancer Treat-
killed through application of the killing force or me- ment Method, Dr. Robert Thomas Gordon, issued Aug.
dium outside of the cell; the only known exception 15, 1978. The outer membrane of the cancer cell being
being, U.S. Pat. No. 4,106,488, Cancer Treatment composed of lipids and proteins, is a poor thermal con-
Method, Robert Thomas Gordon, issued Aug. 15, 1978, ductor, thus making it difficult for the application of
of which this invention is an extension of the technol- 35 heat by external means to penetrate into the interior of
ogy therein described. the cell where the intracellular temperature must be
The extracellular approach is found to be less effec- raised to effect the death of the cell. If, through the
tive because of the difficulties of penetrating the outer extracellular approaches of the prior hyperthermia
membrane of the cancer cell that is composed of two techniques, the temperatures were raised sufficiently to
protein layers with a lipid layer in between. Of even 40 effect an adequate intracellular temperature to kill the
greater significance is that in order to overcome the cancer cells, many of the normal cells adjacent the
protection afforded the cell by the cell membrane in any application of heat would be destroyed as well.
extracellular techniques, the attack on the cancer cells It has been known that the nuclei of cancer cells and
must be of such intensity that considerable damage is the nuclei of normal cells possess some differences. The
caused to the normal cells resulting in severe side effects 45 alterations which occur in a cell to produce malignancy
upon the subject. These side effects have been found to either take place in, or are transmitted to, the nucleus.
limit considerably the effectiveness and usefulness of This is evident by the fact that the cells produced by
these extracellular treatments. tumor cell multiplication possess the same characteris-
A safe and effective cancer treatment has been the tics as the original tumor cell.
goal of investigators for a substantial period of time. 50 A large amount of work has been done "in vitro"
Such a technique to be successful in the destruction of concerning the magnetic resonant frequencies of cancer
the cancer cells must be selective in effect upon the tissues as compared to those of normal tissues. Differ-
cancer cells and produce no irreversible damage to the ences have been attributed to differences in the amount
normal cells. In sum, cancer treatment must selectively of water present in the cancer cells and the way in
differentiate cancer cells from normal cells and must 55 which the water molecules are ordered. A key to this
selectively weaken or kill the cancer cells without af- process lies in the nuclear differences, including energy
fecting the normal cells. changes characteristic of structural and conformational
It has been known that there are certain physical changes in the deoxyribonucleic acid and the histones of
differences that exist between cancer cells and normal the nucleus, including their relationship, resulting in
cells. One primary physical difference that exists is the 60 differential resonant frequencies for the cancer cells
temperature differential characteristics between the from the normal cells.
cancer cells and the normal cells. Cancer cells, because A further key to this process is the additional changes
of their higher rates of metabolism, have higher resting in intracellular biophysical characteristics which occur
temperatures compared to normal cells. In the living in this process. Included in these changes is the intracel-
cell, the normal temperature of the cancer cell is known 65 lular production .of interferon and/or prostaglandins.
to be 37.5° Centigrade, while that of the normal cell is The production of interferon in the past has been shown
37° Centigrade. Another physical characteristic that to be triggered by foreign agents or materials which
differentiates the cancer cells from the normal cells is alter the internal biophysical characteristics of the cell

47c
 4,622,952
3 4
by increases in the intracellular temperature or energy
DESCRIPTION OF THE INVENTION
levels.
Due to the unstable characteristics of interferon and The present invention achieves a precise increment of
prostaglandins, even if interferon and prostaglandins heat rise within the cancer cell and within the cyto-
were to be synthesized and subsequently injected intra- 5 plasm. The thermal barrier that characteristically exists
vascularly into a subject, the effectiveness of the synthe- as the outer membrane or cell wall of the cell is now
sized interferon and/or prostaglandins would be limited utilized as a means of retaining the heat produced
due to the loss of time between injection into the subject within the cell, rather than, as in the past, preventing
and the time when the synthesized interferon and/or any heat build-up within the cell. On the basis of the cell
IO resting temperatures and the temperature necessary to
prostaglandins would reach the cellular level where
produce cell death, the increment that the cell tempera-
their effectiveness is required. Interferon and prosta- ture must be raised to cause the cell death is critical. For
glandins are most effective when their production is the normal cell, the temperature rise is 9.5° Centigrade,
stimulated intracellularly so that their peak effective- while in the cancer cell the temperature rise is approxi-
ness and potential are utilized, where required, intracel- 15 mately 8.0° Centigrade. Thus, any temperature rise in
lularly. the cancer cell or in the normal cell that is at least 8.0°
OBJECT OF THE INVENTION Centigrade and not more than 9.5° Centigrade above
the normal cell temperature results in the selective de-
It is therefore the purpose and principal object of the struction of the cancer cell without any harmful effects
present invention to selectively destroy cancer cells by 20 to the normal cell.
achieving biophysical alterations in the intracellular In accordance with the present invention, there are
structure of the cancer cells while producing no signifi- found to be a number of approaches that can success-
cant effects upon the normal cells. The biophysical fully achieve the end result of an intracellular heat rise
alterations include thermal changes, the stimulation of and an intracellular destruction of the cancer cell.
the intracellular production of interferon and/or the 25 In its simplest and broadest aspect, the invention
stimulation of the intracellular production of prosta- contemplates the use of the differential resonant fre-
glandins. In addition, the present invention provides a quencies of cancer cells and normal cells to allow signif-
technology for the detection of cancer cells wherever icant energy absorption into the cancer cells at their
--they exist in the body. specific resonant frequency while allowing very little
30 energy absorption into the normal cells. The nuclei of
SUMMARY OF THE INVENTION the cancer cells (the DNA, histones, etc.) besides often
A treatment of cancer by the application of external being different in content, usually differ in conforma-
tion and binding from the nuclei of normal cells (the
electromagnetic energy capable of achieving biophysi-
DNA, histones, etc.). These differences contribute to
cal alterations in the intracellular structure of cancer 35 the variance in the resonant frequencies between the
cells in living tissue. These biophysical alterations in- structures in cancer cells and in normal cells. This dif-
clude thermal changes, the stimulation of intracellular ference between the cancer cells and the normal cells
production of interferon and the stimulation of intracel- being nuclear in origin, is transmitted to the daughter
.lular production of prostaglandins. The process com- cancer cells formed by cell division and explains the
-.prises accomplishing these biophysical alterations by 40 daughter cells' propensity towards malignancy.
-:tuning the external electromagnetic energy to the reso- A tuning fork will resonate, absorbing energy, from
nant energy absorption frequencies of the intracellular sound produced by another tuning fork of the same
structure of the selected cells. Alternatively, the field pitch (frequency) twenty or thirty feet away. If a vari-
can be tuned to the frequency which has been calcu- ety of structures were placed within the effective range
lated to be closest to the resonant frequency of the 45 of a high frequency electromagnetic field, those struc-
cancer cells and furtherest from the resonant frequency tures having the same resonant frequency as the electro-
of the normal cells. The process may be further en- magnetic field will absorb energy from the field. There-
hanced by the intracellular absorption of selected mate- fore, by placing the subject within the effective range of
rials designed to alter the magnetic susceptibility and the high frequency electromagnetic field and by tuning
therefore the resonant energy absorption frequency of 50 the frequency of this field to the specific resonant fre-
the intracellular structure. The biophysical differences quency of the cancer cells, the cancer cells will then
between diseased cells and normal cells make possible absorb energy from this electromagnetic field resulting
the selective absorption of materials thereby enhancing in the raising of their intracellular temperature and the
affecting of their biophysical properties so as to selec-
the differences in magnetic susceptibilities between
55 tively destroy the cancer cells without affecting the
diseased cells and normal cells resulting in an increased
normal cells.
capability of selective energy absorption by diseased Computerized axial tomography techniques are com-
cells. This technology has diagnostic applications in the bined with an electromagnetic field generator and de-
detection of cancer cells in combination with the use of tection receiver sensing techniques to obtain three-di-
differential resonant frequencies, magnetic resonance 60 mensional data on specific point resonant energy abo-
and electron spin resonance techniques. The process sorption at a range of frequencies. The resonant fre-
will have application in the treatment of a wide range of quency of the cancer cells being different from that of
diseases at the cellular level, particularly, in the field of the normal cells will serve to identify the location of the
cancer where this mode of affecting the thermal charac- cancer cells.
teristics and of stimulating the intracellular production 65 One possible configuration would embody the sub-
of interferon and/or prostaglandins in the diseased cells ject being placed within a large helical coil and the
will be effective in the selective destruction of cancer entire coil energized by a high frequency generator so
cells without injuring the normal cells and tissue. that the entire subject would be within the effective

47d
 4,622,952
5 6
range of this electromagnetic field. The frequency of the intracellular production of interferon and/or prosta-
this electromagnetic field would be selected as the one glandins.
closest to the resonant frequency of the cancer cells and The intracellular absorption of agents other than
furthest from that of the normal cells. The cancer cells magnetically excitable particles; i.e. various sugars,
will absorb energy at their resonant frequency and will 5 agents affecting cyclic-AMP, a material or materials
be destroyed intracellularly while the normal cells are capable of generating heat intracellularly by chemical
unharmed. reaction and/or the application of an increased oxygen
This destruction of the cancer cells can be monitored supply to the cells resulting in an increased rate of
by repeating the first part after completion of the sec- chemical reaction and increased intracellular metabo-
ond in order to monitor the destruction of the cancer 10 lism can also be utilized to alter the magnetic suscepti-
cells. This destruction can be monitored by observing bility of the cell and to help the absorption of energy at
the absence of cells which absorb energy at the cancer the cancer cell's resonant frequency. The intracellular
cells resonant frequency. production of interferon, prostaglandins, and other im-
This technology has application in the treatment of munological agents, is also stimulated. The intracellular
Atherosclerosis. Research work by the inventor and 15 absorptions enhance the difference in the resonant fre-
studies in the literature suggest that the development of quencies between the cancer cells and the normal cells
atherosclerotic lesions is in many ways similar to tumor as well as to affect the magnetic susceptibility of the cell
formation with the multiplication of a single cell line thereby enhancing the processes in this invention to
and the proliferation of smooth muscle cells (the mono- selectively destroy cancer cells.
clonal theory). These proliferating smooth muscle cells 20 The cancer cells and the normal cells metabolic rate
along with the deposition of cholesterol allow the com- and activity are affected differently by agents such as
ponents of the atherosclerotic plaque to have resonant sugars, prostaglandins, interferon, and agents affecting
frequencies different from those of the normal intimal cyclic-AMP as well as by the intracellular resonant
wall. The magnetic resonant frequencies of lipids in energy changes, themselves. This differential response
bilayers and membranes as well as of phospholipids in 25 of the cancer cells and normal cells metabolic activity
relation to membrane permeability (which of course is allows for a variation with time in the respective reso-
very important to this discussion of atherosclerosis), nant frequencies of the cancer cells and the normal
have been studied. Membrane perturbations by physical cells. These differences can be utilized in choosing the
agents can actually be followed using electron spin specific time when the resonant frequencies of the can-
probe analysis. Using selective irradiation of the speci- 30 cer cells and the normal cells differ the most so as to
men in switched magnetic field gradients, blood flow in enhance the process of detecting cancer cells and the
a vessel can be measured due to the different spin char- process of selectively killing the cancer cells without
acteristics of the new polarized blood entering a specific injuring the normal cells and tissues.
region of the vessel. Studies by the inventor along with "A method according to the present invention is
others found in the literature, illustrate the changes in 35 illustrated in the form of a flow chart in the drawings."
the newly formed atherosclerotic plaques.
Therefore by performing a three-dimensional scan EXAMPLE I
utilizing magnetic resonant sensing techniques, the Determination of resonant energy absorption fre-
areas of atherosclerotic lesions may be identified. Subse- quency for materials or tissues is obtained by using a
quently by subjecting the subject to the frequency clos- 40 high frequency signal generator with the capability of
est to the resonant frequency of the atherosclerotic sweeping the frequency range to be scanned which is
lesions, the lesions may be destroyed due to the absorp- connected to an antenna. A receiving coil connected to
tion of energy, without affecting the normal vessel wall a power meter (so as to measure the power received) is
whose cells respond to a different set of frequencies. placed a short distance away. The material or tissues
The uptake of particles by tumors and atherosclerotic 45 (whose resonant absorption frequency is to be deter-
plaques in certain stages of their formation has been mined) is placed in the space between the transmitting
demonstrated. Magnetic resonant sensing techniques antenna and the receiving coil. Appropriate shielding is
may be utilized to characterize the magnetic parameters placed laterally around the specimen being tested in
of the structures. Electron spin probe analysis has been such a manner that any RF energy being transmitted
used to detect membrane perturbation by physical 50 from the antenna to the receiving coil must pass
agents. By allowing the tumor or atherosclerotic plaque through the specimen. As the frequency range of the
to take up the particles, be they ferromagnetic, para- signal generator is scanned and the power received by
magnetic, or diamagnetic, the process of determining the coil is measured, the resonant absorption frequency
the resonant frequencies of the cancer cells or the ath- for the specimen being tested will be indicated by a
erosclerotic lesions and of energy absorption at the 55 significant drop in the power received by the receiving
desired resonant frequency, may be enhanced. coil (since at this resonant frequency, the specimen will
The production of interferon is triggered by a foreign be absorbing some of the power).
substance which the cell senses. A magnetically excit- This method will be applicable to determining differ-
able particle which is absorbed intracellularly by the ent resonant absorption frequencies for cancer cells and
tumor cell and then magnetically excited, results in 60 for normal cells and for the various additive materials.
energy absorption, temperature rise, and some mechani- The method will also be useful in measuring the alter-
cal vibration, which acts to trigger and to stimulate ation of the resonant absorption frequency by the intra-
interferon production as well as prostaglandins produc- cellular absorption of various materials and by changes
tion in the cell and other intracellular immunological in the intracellular metabolic rate.
responses. These responses aid in the processes' ability 65
to destroy the cancer cells. The intracellular absorption EXAMPLE II
of resonant energy, alone, will excite and alter the intra- As a specific example of the simplest form of the
cellular biophysical characteristics and will stimulate present invention, prior to treatment, tumor tissue biop-

47e
 4,622,952
7 8
sies are taken and examined under light microscopy to absorption of oxygen. The increased rate of intracellu-
confirm tumor cell identification. 2 cc. of an aqueous lar oxygen absorption, especially by the cancer cells,
colloidal solution of FeOOH and dextran is injected coupled with the already intracellularly absorbed ferric
intravenously into the subject. This solution when in- oxyhydroxide, results in an increased rate of oxidation
jected intravenously is capable of being intracellularly 5 and metabolism of the ferric oxyhydroxide and there-
absorbed and thus greatly increases the magnetic sus- fore in a significant rise in intracellular energy. This
ceptibility of the intracellular. structure of the cell. significant rise in intracellular energy further results in
Moreover, after this solution is intracellularly absorbed, intracellular thermal changes, stimulates the intracellu-
it is capable of being metabolized by the cell thus pro- lar production of interferon and/or stimulates the intra-
ducing a variable magnetic susceptibility with reference 10 cellular production of prostaglandins, resulting in a
to time. Biopsies taken several hours after the intrave- destruction of cancer cells wherever they exist in the
nous injection of the solution and examined under elec- subject.
tron microscopy, confirm the intracellular absorption of
this solution, particularly by the cancer cells. Biopsies EXAMPLE IV
of cancer tissue and normal tissue taken at I hour, 2 15 The subject is placed on a table with the electromag-
hours, 4 hours, 12 hours, 24 hours, and 48 hours after netic energy transmitter on one side and the detection
the intravenous injection of this solution are immedi- receiver on the opposite side. The transmitter and the
ately frozen and subsequently taken for measurements receiver are on a moveable axis which can rotate 360°
of magnetic susceptibility in a Vibrating Sample Magne- and move laterally the length of the subject. The fre-
tometer, Princeton Applied Research Model No. 159. 20 quency is varied from 1 Kilohertz to 50 Megahertz at
Using this data, it is possible to plot the rise in magnetic each point on the 360° circle. The input from the detec-
susceptibility due to the intracellular absorption of the tion receiver is fed into a computer which composes a
solution in the cancer cells and to compare it to the three-dimensional picture of the resonant frequencies of
magnetic susceptibility changes in the normal cells. This all points in the subject. The distribution of cancer cells
gives data on the increase in magnetic susceptibility not 25 is noted as is their resonant frequency.
only due to the intracellular absorption of the solution, The subject is then placed in a large coil approxi-
but also with reference to the matabolism in the time mately 3 feet-6 feet in diameter. The coil is energized at
period. Using frozen samples from a time period which the frequency determined by the computer. The subject
indicates high relative magnetic susceptibility of cancer is then treated for an increment of time determined from
.. cells to normal cells, and using the method described in 30 computer data. This increment of time could range
Example I earlier, for determining the optimal resonant from 2 minutes-30 minutes. Approximately 48 hours
absorption frequency, it was determined that a high later, the subject is placed back on the original table and
frequency electromagnetic field of 450 kilohertz applied the procedure of detection repeated. Should any cancer
approximately 4 hours after the intravenous injection of cells with their specific resonant frequency be detected,
this solution, would provide optimal resonant energy 35 then the subject is treated again, etc.
absorption and resultant biophysical alterations by the There are many variations of the invention as de-
·cancer cells. Approximately 48 hours after this proce- scribed and this invention should be limited solely by
- dure was followed, biopsies are taken and examined the scope of the following claims.
. under light microscopy and electron microscopy which I claim:
confirmed the effectiveness of this procedure in de- 40 1. A process for the treatment of cancer cells in a
--.straying cancer cells without injurying surrounding subject's living tissue comprising the steps of:
normal cells and normal tissue. determining a resonant absorption frequency of said
cancer cells,
EXAMPLE III generating an electromagnetic field,
Basically this invention relates to achieving biophysi- 45 turning said electromagnetic field to said absorption
cal alterations in the intracellular structure of living frequency of said cancer cells, and
cells, particularly cancer cells, by raising the energy exposing the subject to said tuned field to achieve
level inside the cells, intracellularly. The application of biophysical alteration in said cancer cells' intracel-
energy derived from chemical reaction can be utilized lular structures, said biophysical alteration includ-
for this purpose, for example; ferric oxyhydroxide parti- 50 ing the stimulation of intracellular production of
cles of0.7 micron size are colloidally suspended in a 5% interferon.
dextrose aqueous solution in an amount of approxi- 2. The process according to claim 1 further compris-
mately 50 mg. of the particles per cc. Dosages in the ing the step of:
amount of 30 mg. per kg. of body weight of the subject intravenously injecting into said tissue metabolic and
are intravenously injected. Techniques described in 55 activity varying substances to alter the biophysical
U.S. Pat. No. 4,106,488 may be employed to more selec- characteristics of the intracellular structure of the
tively direct the particles to the cancer cells. Approxi- living cell.
mately 4 hours after injection, particles will have been 3. The process according to claim 1 further compris-
intracellularly absorbed by the cancer cells. Subject is ing the step of:
then placed in a hyperbaric oxygen chamber and sub- 60 introducing into said tissue intracellular chemically
jected to an approximate 50% oxygen concentration at generated energy substances to stimulate the intra-
a pressure of 3 atmospheres for a period of approxi- cellular production of interferon.
mately 3 hours. Normal hyperbaric chamber safety 4. A process for the treatment of cancer cells in a
procedures in achieving compression and decompres- subject's living tissue comprising the steps of:
sion would be followed. 65 determining the resonant absorption frequencies of
The hyperbaric oxygen chamber procedure would said cancer cells,
serve to raise the oxygen level of the subject's blood determining the resonant absorption frequencies of
which, in turn, would raise the rate of intracellular the normal cells of said subject,

47f
 4,622,952
9 10
calculating the frequency closest to said resonant 10. A process for the treatment of cancer cells in a
frequency of said cancer cells and furtherest from subject's living tissue comprising the steps of:
said resonant frequency of said normal cells, determining the resonant absorption frequencies of
generating an electromagnetic field, said cancer cells,
tuning said electromagnetic field to said calculated 5 determining the resonant absorption of the normal
frequency, and cells of said subject,
exposing the subject to said tuned field. to achieve calculating the frequency closest to said resonant
biophysical alteration in said cancer cells' intracel- frequency of said cancer cells and furtherest from
lular structures, said biophysical alteration includ- said resonant frequency of said normal cells,
ing the stimulation of intracellular production of 10 generating an electromagnetic field,
interferon. tuning said electromagnetic field to said calculated
5. The process according to claim 4 further compris- frequency, and
ing the step of: exposing the subject to said tuned field to achieve
intravenously injecting into said tissue metabolic and biophysical alteration in said cancer cells' intracel-
activity varying substances to alter the biophysical 15 lular structures, said biophysical alteration includ-
characteristics of the intracellular structure of said ing the stimulation of intracellular production of
cancer cell. interferon and the intracellular heat rise of said
6. The process according to claim 4 further compris- cancer cells.
ing the step of: 11. A process for the treatment of cancer cells in a
introducing into said tissue intracellular chemically 20 subject's living tissue comprising the steps of:
generated energy substances to stimulate the intra- determining the resonant absorption frequency of
cellular production of interferon. said cancer cells,
7. A process for the treatment of cancer cells in a
generating an electromagnetic field,
subject's living tissue comprising the steps of:
tuning said electromagnetic field to said absorption
determining a resonant absorption frequency of said 25
frequency of said cancer cells,
cancer cells,
generating an electromagnetic field which includes intravenously injecting into said tissue metabolic and
energy with variable frequency in the range of I activity varying substances to alter the biophysical
kilohertz to 50 megahertz, characteristics of the intracellular structure of the
tuning said electromagnetic field to said absorption 30 living cell,
frequency of said cancer cells, and said biophysical characteristics inlcuding the mag-
exposing the subject to said tuned field to achieve netic susceptibility of said intracellular structure
biophysical alteration in said cancer cells' intracel- and therefore the resonant energy absorption fre-
lular structures, said biophysical alteration includ- quency of said living cell, and
ing the stimulation of intracellular production of 35 exposing the subject to said tuned field to achieve
interferon. biophysical alteration in said cancer cells' intracel-
8. A process for the treatment of cancer cells in a lular structures, said biophysical alteration includ-
subject's living tissue comprising the steps of: ing the stimulation of intracellular production of
determining the resonant absorption frequencies of interferon.
said cancer cells, 40 12. A process for the treatment of cancer cells in a
determining the resonant absorption frequencies of subject's living tissue comprising the steps of:
the normal cells of said subject, determining the resonant absorption frequencies of
calculating the frequency closest to said resonant said cancer cells,
frequency of said cancer cells and furtherest from determining the resonant absorption frequencies of
said resonant frequency of said normal cells, 45 the normal cells of said subject,
generating an electromagnetic field which includes calculating the frequency closest to said resonant
energy with variable frequency in the range of I frequency of said cancer cells and futherest from
kilohertz to 50 megahertz, said resonant frequency of said normal cells,
tuning said electromagnetic field to said calculated generating an electromagnetic field,
frequency, and, 50 tuning said electromagnetic field to said calculated
exposing the subject to said tuned field to achieve frequency,
biophysical alteration in said cancer cells' intracel- intravenously injecting into said tissue metabolic and
lular structures, said biophysical alteration includ- activity varying substances to alter the biophysical
ing the stimulation of intracellular production of characteristics of the intracellular structure of the
interferon. 55 living cell,
9. A process for the treatment of cancer cells in a said biophysical characteristics including the mag-
subject's living tissue comprising the steps of: netic susceptibility of said intracellular structure
determining a resonant absorption frequency of said and therefore the resonant energy absorption fre-
cancer cells, quency of said cancer cells, and
generating an electromagnetic field, 60 exposing the subject to said tuned field to achieve
tuning said electromagnetic field to said absorption biophysical alteration in said cancer cells' intracel-
frequencies of said cancer cells, and lular structures, said biophysical alteration includ-
exposing the subject to said tuned field to achieve ing the stimulation of intracellular production of
biophysical alteration in said cancer cells' intracel- interferon.
lular structures, said biophysical alteration includ- 65 13. A process for the treatment of cancer cells in a
ing the stimulation of intracellular production of subject's living tissue comprising the steps of:
interferon and the intracellular heat rise .of said determining a resonant absorption frequency of said
cancer cells. cancer cells,

47g
 4,622,952
11 12
generating an electromagnetic field which is external being absorbed in said cancer cells to enhance the
of the subject, determination of the resonant absorption frequen-
tuning said electromagnetic field to said absorption cies of said cancer cells,
frequencies of said cancer cells, and determining a resonant absorption frequency of said
exposing the subject to said tuned field to achieve 5 cancer cells,
biophysical alteration in said cancer cells' intracel- generating an electromagnetic field,
lular structures, said biophysical alteration includ- tuning said electromagnetic field to said absorption
ing the stimulation of intracellular production of frequency of said cancer cells, and
interferon. exposing the subject to said tuned field to achieve
14. A process for the treatment of cancer cells in a 10 biophysical alteration in said cancer cells' intracel-
subject's living tissue comprising the steps of: lular structures, said biophysical alteration includ-
determining the resonant absorption frequencies of ing the stimulation of intracellular production of
said cancer cells, interferon.
determining the resonant absorption frequencies of 16. A process for the treatment of cancer cells in a
the normal cells of said subject, 15 subject's living tissue comprising the steps of:
calculating the frequency closest to said resonant introducing into said tissue substances capable of
frequency of said cancer cells and furtherest from being absorbed by said cancer cells to alter the
said resonant frequency of said normal cells, biophysical characteristics of said cancer cells,
generating an electromagnetic field which is external determining the resonant absorption frequencies of
of the subject, 20 said cancer cells,
tuning said electromagnetic field to said calculated generating an electromagnetic field tuned to at least
frequency, and one said absorption frequencies of said cancer cells,
exposing the subject to said tuned field to achieve and
biophysical alteration in said cancer cells' intracel- placing said subject within the effective range of the
lular structures, said biophysical alteration includ- 25 electromagnetic field and exposing the said subject
ing the stimulation of intracellular production of to field to achieve biophysical alteration, including
interferon. the stimulation of intracellular production of inter-
15. A process for the treatment of cancer cells in a feron, in said cancer cells' intracellular structures.
subject's living tissue comprising the steps of: 17. The process according to claim 16 wherein,
intravenously injecting into said tissue particles se- 30 said placing step commences before said generating
lected from the group of ferromagnetic, paramag- step.
netic, and diamagnetic materials and capable of * * * * *

35

40

45

50

55

60

65

47h
 o,._ N~'f.;,,1h.e,r 18/ l</?6 1 Robe11f r: ~don.. «.ttUJ yro1 1 /.eel ct
pa.le-K,I jW' a. Fre_.y1."e1/t.eAj .Inf>· frv~ -hv~~ caitcer-.

/J<:Z1e.s t<_/ I -I-IL ~ I d I a f nr:.,

G-oyoc;/(7;1 s 11a. Yevd- IS a. s Ir (Jr I I 01. ra
a11d. Y-ha..T ~ a. sl<e~/._ " / t:he proces>. t.f-r,rc(t:>U. /Jas
~')(per~n<i',,,,uf.ed A-~ w1../-lt_an11n~ls - ~ 1nalC2s 110 c./4/11:s· ~
a..,_Y /11st-~1~/ Auf 111s1'-ead vses ex1s f1;1y -kc/.,,,o/~y . .
(J-J~jl h~s are {36),,,. N Cerr'-a1lc.j mtfkf- 6-a- t<JorHi t-<./?7r-/:.11t9
w1~ /,l.>e.R£ 1ulo ~ ~-fure._ 1
(J.o")'<d~ IS 110T ffen!//l-11i7 "'"° dev1'fo..l1J. € c·a11cer m1cro.6e.s
0

&{.

(,U1#.. /11s. ..,e~j ~nc..y ./ /:Ju~ 111 s fep_d Cl tfa.c/c ca11cer c e//:s .
He does -l-11 is. 11~ Yu.re tuays - i3eca..c1se a. CaJtce; ,cell cui·11
f
Ir /11CHaSt°S Ill. A..eaJ- Py. 8 . 0 Cei-1 l-r71·~
k de.sfroyec/
tv/1t'/e Q.. t1<!Y"1ni.r..J? Ce// /$ des trcyec/ r
tf- IJzcrea !i....t?S
trcrdon 15 V.>11ty ~r<-fv~i?Y ./o 11~':'-'T- t:a11c·er cells /}.asl- c?. o"
'j'. $c~

0
bvV- /<:>rs f-/1a~ 9. 5. /.k. de ~rn-t1K.a-1 a Se!Jara:Ze .P~f""-er:/
f'es,711<11zt:e ~.,... ~- c~a/1c~r r:e. 1/s CVJ.1d /Jor1?"1d c.: e_//s
~la 1~1~iy f-ha.:t .511-i(e ri.R ~f.-e1""'1~- k~---i<.. +I~. fre/-..~"tct~..r
/artt-5 VJt ../lt. Q 11V1YJ_k,,,- '1
~c~/ -/-Jui f-1¥.a.. ~ () Cc.vt:'S
0~...
#-.e. ~N!JileltCit'.S a:A.e l??o s.,.:.... d t.5 fa~ Tie i7o hc/J't.. IS
fo ~ v'4:. ca.-1tc.ar cells -4v~ Te> lzeCl:f- r'..£.e Cc<;1c-er
~e 11 -F'1¥--nt W t II? 1 Pt, . .
O/ c~_,1 -l-h1.s hC< s /lo r:j/ee-f- (}'Yl ~- t.'ancer n-?tcrok
? lse~AJZ ,-"- ~~- he~ CV1-1d /112 /1us 110 wa.y de.. ki·;1:1 1>~1;1
1-/uz_ c'u11{e.r m 1c 1-okc:;. j- !A'€::1 ~. / es kb I,~
~ pa le__~ Ar a c/t;.5 Cl-() 11 / i-J'e-({../,~ ca-~~ 1vz_

lh- '/e - Cra11.<!_ Cu 1-'1c·er v'-N'a_~t:t-.

tf.o ,. .dtrK a Is o er I ea1--y .s tr"' le.cJ Hi a.A r re< d 1l-c
~ ea J1 ce r (?')"]

1-f'&al-nt.£~ - S"Ur,erc; I J"a.d {(A. ntl'>?./ CJl~mo. ~ra.ry- aA..e_

:'e X frac e /lu la r-, / fl 1.s 1~ /1 rs f _ 111 fra (e. /lu la r cLfJ/Jrc~ _
Ve o.../s o ~ ~"!:!f<H:U-Z~ ~ S frJnv /~ ffo....e_, body 1s
t>r(J d ue- frvn. 1
11ifer/?el'on.
<fJ l/ o .fa_ fr r·n s cPr.o'n--1 /7 rs pa -/..e,,,.,,,d ~ I Iow .
 ,4 /Jl'()(.es£ vL-~ f-/t.e 1-rr:-a .f11:e1z f of c'a11ce,- I.> riv:. .yvlrra frf.n
1. e X fff"hct..R e/ec. f-ro rY1t:.l'j'l1 f' .hc e/)~/'~f C'C<_pa. 't,/e_ /'a(./, ft' V'-!!_J
L-. '0 JOl7'f5i('a...P ffe1~a. 1-rn-z.s Ill . flu 111fra ~C'. //ule<r .,5° l-1·vc rv1-e
tl..
0
1
CC: 11c ei" L"e/Is 1/z /1' i.-~ 111J _ -l-1 s .s <.:e./ 1n c.luc,,/1~1j 5 ./-1111,,1 la. h~ it '1
1117-t"Ctceilular prcidvc. 1-t~n ."/!rt ff'1~./?e 1'P'n. ,. TlV?.. f!lr .:7 c:e.s:..s. .
l1 C(.V"J?1p/1shes rhc-se. 1-l-e!'a. ht1't~· P'f -f-un1ny
l>1o;oAys.1ca.R a
a11 exlernt-<.P e l~c fromafr1e. tee . erJe177y ./o ~lv2 l"lsl/Y7Q11 r.:.
e11e119''/ a.. .bs(Jrp -l-10/l ..,ere-t(./e11<1es 6j -1-he In fre<ce 1/u.lcl('
sfruc-1-v~e 7
-H1e s_·e f<-'c. f~cl ce. l/s a11d +-A e1z. e xpo.s· 1~y
f-lie .St.Jb1 ('c., -f- riv V-J: 1..s
-l-u11~cl _e lee_-!-/'" /Y?Cl.j i7 e n. c en er..J 7
-f?/e./d ~ A lfernu ltve!y -1-ll.€ ~,e /cl ct0-t. k ./-(,11?~d ~ ./-/u;>_
1
.t:!re_rue;.1/ CA->h1cl7 /1as bee1t ra.lcu/o.. ft?d ./o ,be. -./-/1..12_
c(e>sesf;) .fc -f-lte. reso1?a1zr ./-J.·etve1-1cy 1-M. c~nc·er cells c:/
a i1d +.ur 1-h 6 s r- .c'ro1n +he. re .s (:J1?01-z ../J-e uen ~ t-11 e_ r r cy
no1"rY!a/ Ce.Ifs, TILe f>i'oc ~ss rn~ be ../u~l-Aer eri'han~ Pd
h'/ f-/1~ . 111 fra.ce.//c...>/cer a bsorp /-1vx.. . .selec~c/ ,ma fer1als

+-h~f"c-? /!ore . f-A.e_ r<:> s C/YJu J. z. r-.

eneri9 f uh&<:;;·;:> -l-1vn }-e-f' V i" r7<.J
o ../- +A.e 1"1 fm ce //u la1~ s f1~u<. . fu!'e .
Oh1_'f'<..,f 7 Ihue11 fr,'h : 5<? 1ec.... f1ve-'7. d _£>!:.r/-':<Kf cc~11c-e1· <.ell~ _ ,b/
a c.11, -e "': ''"'i b ro ;o J! y s 1ca.f a I f e 1~a. t7 nr s; ,/ i t f /Li2_ 11-1 f-1:'« c e I Io la,.~. _
8'f-ru.:. fvr'<:'.. ""(+lte.. . ('a1zc·e:;· C"~ /ls tA.)/111::._ p1·(>do.:1.~1y 11 0 .s1y1111'1caYlf
Ct /? ~ec.. f~ vpcrn f-)1..('. norntc( I ee. //5 . I~ ,b I 0 jOh ys IC o...(7 Cl /ft:'/''{ T/CIYJ5
i11clv<'le . -f-/1e.1•n1c,(,I c/1u117~s / -1-/Le__ .s i-1.11-:'~'la l-r1-1t .f-/, 0 "f
/ t? fra. Ce 1/c..• /a r /> rc1 cJ U<- ~ crt ttf .
i/1 fer ,,t:°e r<TYL a..,,_1c{/ 01-. ~ -f-J, ~-
S .../-t'fflv· /a_ frm f-1~ /11 f-ra.. c~ //c..'/a1- ;0radc/c. I-rt-~ o .P .
er(
? r i) ~ f a J I a 17 d 111 s . In C:(. d d I fr ( }t f-h. e fJ res~11. r I 17 v e 1'7 l-1 c/}1_
J>ro,,-,·df' ..s c;e fe c/?,110/oJ l/ ..f?_c., .. c;te l-e c l-1V>1. f-k ca 1 1<.F'1~ 7
Ce 1(.s w/1&rever f-/iey ex IS f- ;k.... f-/t.e. ,b ocftY- . .
llte .f,•e/d Cate fo e. .f.u1-1~d. <Iv rite .f1re;uenc'j wh 1c~ lc.. hc<s
hee 1--:.. c•a/cc~ lcr.fecl oLo b e c./ose.s f- <1-v f-he res 017a.Yt.r
..Pre '6 ve 1--t c.y <>( Y-11 e ca 1-z c ~ ;- c e,/ / s a 1~ d ..f?u,,.. Ht. e 1· e .s i-
r:/"ro ,-n f-J1e 1~eSO/"?Ql-t f- +re pve1-1e-y 7 r/.1e )?OJ·yy1ec(} Ce.//.s .

/3.y f> /C-'.C. 'I. i-ly -f-/1 e ~; Ub/eC....T lA..J ~. ~,Bee. ft Ve rc7 ll/ e
1'f-/,1 th_ 'f-h e_
o /! f-/1 e /1 'J
h.. +1·~ f v~ it '-'l e I~ c- f-r o /Y1 a n ~ h c":. Fi e_/cl a 41 c:( 7
,.by fu111~'J +lze. ,L:;.e..fL'~J1 <-L/ °I
~/1 15 ./'1·e .ld ~' -l-l1t:' 5jJ<"<. ,·/~c.:.
~f>sa1?<.11tr .f?;·Pg L1 ei1cy ~ l-/1 e. l'e<1-1(C'/~ <~/Is/ f-he cc:t11<~1-
< e. 1 /.~ I /1 ~ "t (.._, ' / / a 1: s· C? r .b & J1 ~/"'/'I /re~ -/-/1 c.S
e If'('. fro 1-vt (JJ )':le, r t C ..,L: / e l <f re:- s· ( / I f InJ JI-<- t-lv:. /<;(I .S l(·r y
 ;°/ -/-/1e_1r 1_izfrace//'":l~r fe1n/'era.l-ure. CJMd -1-lte a~.,£::,c. _"71-j
. . ~ .f-he Jr b 10 pAys 1ca.R Jiro,,Qe/.,rlt<-S so . as -lo Se/<!'"'(.., f-1ue 7
oles froy_ -l-l1e C'Cl11ce.r Cells wlv'/,our a ./?/'t'e-/-11-19 -1-fte_
/101~1-na..e. cells .
Cot->l~U ./-ei•/J .e c/ ax 10-.P 1-ontoyr,zpAy fee./; 111 gue s Cll'e CC/1'1 ;b1;~ecl
UJt flt a_Jt e lee fro /h~ne v'tc ~, e id 7e n era:lor a1-1d de f-e.c ltci<
. _ re~e1ver_ sens /nl ~ech/'71gue-s _ ./-o o_b fr::~ 1~c. -!-hre.e -
·d 1l?'1e1-1s ~Ph_o.0 da.'hA. pVL. spec 1/:_c /f/Oln f- /e SO/?a~1 T ene/tj'_j
a b5orr: r1<7k a;t- o. ru11ye °(
~e {ue.11~·1es. w res·o11a1c.. f-
.f?,e-rue_1-1:i '?/ -t-Ae cqncer ce./ls . be/;t.J d1'~/'ere1-? f vf?r(7)'K
-f-ha:._;I- crjJ ..,U~ 1"7CJY'rn"'2 ee//s w 1 { / 6·erue lo ;·~A/l.h'h;
f-/'42. Io t a ./r ex °/ ~A e t'a 11 c er e e 11s .
0 n e. p o :s s , 'b ~e c:tJ'Yl .f?,Ju/"(:,(_ 1-rvX w ouId .e 1-n .6 o c.iy ~Ii "€..-
~- (J b ;'ec..; f- be' "'J /'la(. ~d w 1fl: 1;c., 1 a lu rye A e I 'c ~
co1'/ ~1d ~/ze e17 fire. coil e11ery1y~cl ~a hrjlc_
..Pree? uetzcy <JC:/1.e~a. ~ so f-ha.;f- . .f-/~ e11 .fire sub/~..c~
<-Vou td b Q._ G.U 1 Ht_11<. -riv;_ effec ftve /'a 1-?r- t-/1 rs °/
el e c fro !'haj 1u. ft c ~·e Id,